Diskussion zu Dynavax Technologies - 500 Beiträge pro Seite (Seite 3)

[Lucky72]

[Elmshorner]

Antwort auf Beitrag Nr.: 37.957.564 von Lucky72 am 10.09.09 20:24:48

3 € ...das kann schnell gehen...aber Rom ist auch nicht an einem Tag erbaut worden

[Elmshorner]

Bei dem Kursanstieg könnten auch Leerverkäufer ihre Hände im Spiel haben.

[Lucky72]

Antwort auf Beitrag Nr.: 37.957.723 von Elmshorner am 10.09.09 20:44:57

Wie kommst du da drauf?

[Lucky72]

Shares Float 16,630,000
Total Shares Outstanding 39,925,135
% Owned by Insiders 15.49 %
% Owned by Institutions 32.00 %
Market Cap. $ 104,216,580

[Lucky72]

http://www.mffais.com/dvax

[Sundaysdinner]

Gut, Bauch hat richtig gelegen,man sollte doch nicht immer sofort aufspringen, wäre heute ein herber Verlust.

Morgen dann 1,60-1,70€ und auf die 1,25€ zurück?, war mir auch ziemlich suspekt der Anstieg mit nicht mal 40.000€ Umsatz in Fra.

[Lucky72]

Antwort auf Beitrag Nr.: 37.958.272 von Sundaysdinner am 10.09.09 21:52:20

Es gab News oder hast du das vergessen?

http://news.google.de/news/search?um=1&ned=de&hl=de&q=Dynava…

[Lucky72]

Guten Morgen!

[Lucky72]

10.09.2009 23:57
UPDATE 4-Dynavax shares soar as hepatitis B trials resume

By Toni Clarke

BOSTON, Sept 10 (Reuters) - Dynavax Technologies Corp said on Thursday that U.S. regulators have given it the green light to move forward with its experimental hepatitis B vaccine, sending the company's shares up nearly 46 percent.

The U.S. Food and Drug Administration placed the product on clinical hold 18 months ago due to safety concerns. Dynavax presented additional data to the agency, which has now given it the go-ahead to immunize patients with chronic kidney disease who do not respond well to an existing product.

The news surprised investors, who had largely written off the vaccine, Heplisav. Last November the company's shares fell to 15 cents, down from more than $10.00 in late 2006. They closed up 80 cents at $2.55 on Wednesday, having trading as high as $3.35 earlier in the day.

Hepatitis B is a chronic disease which can lead to cirrhosis of the liver. There is no cure for the condition. The only vaccine on the market is Engerix-B, made by GlaxoSmithKline Plc. Dynavax believes Heplisav is more effective and can be given in fewer doses than Engerix-B.

The FDA put Heplisav on hold last March after one patient developed a case of Wegener's granulomatosis, an inflammatory autoimmune disease that affects the small blood vessels and can cause extensive tissue damage.

Bret Holley, an analyst at Oppenheimer&Co, said the company may not have enough money to fund the trials required for approval and warned that any new safety concerns could derail its future.

'We believe sharp upside on today's news is appropriate but expect Dynavax to trade in line over the near- to mid-term with few upcoming catalysts,' he said.

Heplisav combines a genetically engineered viral antigen with an adjuvant to create its vaccine. The adjuvant, designed to enhance the effectiveness of the antigen, targets Toll-like Receptor 9, a protein that tells the immune system to activate itself.

Dynavax, which is based in Berkeley, California, has completed a late stage trial of the vaccine, and said its next step is to enroll patients in a trial to compare vaccine made for commercial use with that made for use in clinical trials, to make sure they are the same.

Dynavax Chief Executive Dino Dina said the company expects to complete the process by end of 2011. If all goes well, the vaccine could reach the market by the end of 2012 or early 2013.

Dynavax is also using its adjuvant in a different form to develop a universal influenza vaccine that can be used for seasonal and pandemic flu. The vaccine is in pre-clinical development.


http://www.finanznachrichten.de/nachrichten-2009-09/14920486…

[Lucky72]

Time & Sales
Price Size Exch Time
2.58 1000 NGS 19:59:28
t 2.61 1500 NGS 19:55:06
t 2.60 100 NYE 19:53:35
2.60 1000 NGS 19:51:35
2.60 200 NGS 19:51:35
2.61 582 NGS 19:41:28
t 2.61 100 NGS 19:34:57
2.61 546 NGS 19:33:33
2.61 100 NYE 19:31:43
2.61 500 NGS 19:31:43
t 2.61 800 NYE 19:29:54
t 2.61 240 NYE 19:28:00
t 2.61 800 NYE 19:28:00
t 2.61 200 NYE 19:26:19
2.60 185 NDD 19:25:33
2.60 1000 NDD 19:23:34
2.59 800 NDD 19:22:58
t 2.58 3000 NYE 19:13:20
t 2.59 200 NYE 19:09:58
2.60 2500 NDD 19:09:16
2.60 1054 NDD 19:07:10
2.60 906 NDD 19:04:18
2.60 315 NDD 18:57:38
2.60 300 NDD 18:57:38
t 2.61 315 NGS 18:57:38
t 2.61 150 NGS 18:57:34
2.60 100 NDD 18:52:47
2.60 500 NGS 18:48:43
2.60 1000 NDD 18:48:17
t 2.60 140 NGS 18:46:37

[Lucky72]

Nur zur Info!

http://data.cnbc.com/quotes/DVAX



http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

Hier ist der Link zur HP!

http://www.dynavax.com/

[strike321]

Nicht zu vergessen, DVAX besitzt wieder Weltweite Rechte an HEPLISAV™. D.h. für mich, eine Partnerschaft wird jetzt nach der wichtigen FDA Entscheidung nicht mehr lange auf sich warten lassen

Die 4 USD kommen m.M. nach bei nicht einbrechendem Gesamtmarkt in den nächsten Tagen/Wochen trotzdem, auch wenn die gestern im Hype nicht erreicht wurde

[Sundaysdinner]

Alles schön und gut, dennoch geht es erstmal wieder runter, also waren die Kurse gestern in DE übertrieben, Elmshorner hatte es ja schon angedeutet.

Das es jetzt weiter steigt sehe ich noch nicht, Fakten sind Positiv aber leider schlägt sich das im Kurs noch nicht so nieder, der gestern um die 2,10€ gekauft hat ist heute schlauer.

Bin gespannt auf die Eröffnung in den USA ...

PS: würde mich natürlich freuen wenn ich falsch liege und heute noch mal 100% anstehen!

[Elmshorner]

Antwort auf Beitrag Nr.: 37.960.729 von Sundaysdinner am 11.09.09 10:42:22

Gestern haben viele ihre Gewinne realisiert...es könnte heute oder Montag wieder nach Norden gehen.

[strike321]

Antwort auf Beitrag Nr.: 37.960.729 von Sundaysdinner am 11.09.09 10:42:22

Heute werden wir sicherlich keine 100% sehen, aber 10-15% könnte es bei positivem Markt schon werden.

Die Kurse werden in den USA gemacht und nicht in Deutschland. Kurse um 2,10€ sind ca. 3 USD und die hatten wir ja nun überwiegend gestern in den USA.

Alles im allen war die gestrige Entscheidung sehr Positiv für DVAX und das wird sich auch bald im Kurs wiederspiegeln.

[Sundaysdinner]

Antwort auf Beitrag Nr.: 37.960.850 von strike321 am 11.09.09 10:59:00

3 USD und die hatten wir ja nun überwiegend gestern in den USA.
Sorry. aber anscheinend hatten wir unterschiedliche Charts, 20 min und dann waren die 3$ dahin ab da hin ging es nach unten bis 2,55$, und das sind 1,75€ also auch schon wieder weniger als im ASK steht.

Für mich war ja auch nur der einstieg zu 2,10€ relevant, Leute die zu 1€ oder niedriger hier drin sind die haben schon ihre % gemacht.

Kann sein das ich den einstig verpasse aber so hätte ich ja jetzt schon satten Verlust gemacht.

[Elmshorner]

Pre-Market sieht man wohl erst ab 13.30 Uhr....oder?

[strike321]

Antwort auf Beitrag Nr.: 37.961.163 von Sundaysdinner am 11.09.09 11:29:13

Hast recht, ich hatte nur 2-3 mal gestern im Laufe des Tages in ein Orderbuch geschaut und immer Kurse um 2,75 -2,80 USD gesehen.

Das ändert aber nichts daran, dass jeder der in Bio investiert schon wissen sollte, dass es keine Einbahnstraße ist.

Du hast doch alles richtig gemacht in dem du den gestrigen Tag hast laufen lassen, um nicht bei Höchstkursen einzusteigen.

[strike321]

Antwort auf Beitrag Nr.: 37.961.765 von Elmshorner am 11.09.09 12:34:11

Spätestens ab 14 Uhr sollten wir Pre-Market Kurse sehen.

[Elmshorner]

Antwort auf Beitrag Nr.: 37.962.007 von strike321 am 11.09.09 13:06:43

Danke, vorb. Kurs 2,7....da geht doch noch was. Welche Realtime-Anbieter nutzt ihr für die USA ?

[mazuba]

Antwort auf Beitrag Nr.: 37.962.548 von Elmshorner am 11.09.09 14:11:23

http://www.level2stockquotes.com/level-ii-quotes.html

[Elmshorner]

Antwort auf Beitrag Nr.: 37.962.698 von mazuba am 11.09.09 14:31:27

danke, sehr gut.

[Sundaysdinner]

Tja, das war es wohl dann erstmal, wie ich mir gedacht hatte trotz News ist der Hype erstmal ausgeblieben mit den 15% + wird das wohl auch nichts.

Ist natürlich schade das der Anstieg nicht einmal 1 Tag anhält, bei den Aussichten hätte sie doch Explodieren müssen.

[strike321]

Antwort auf Beitrag Nr.: 37.964.457 von Sundaysdinner am 11.09.09 17:36:02

Vorbörslich sah es ja gut aus

Das ist halt Börse und vorallem Bio.
Die Aussichten bleiben trotzdem hervorragend und der Kurs wird es mit der Zeit wiederspiegeln.

[Lucky72]

[Sundaysdinner]

Antwort auf Beitrag Nr.: 37.965.630 von Lucky72 am 11.09.09 20:33:40

Nicht mehr viel dann haben wir die 1,10-1,25€ von Gestern Morgen wieder, vieles hätte ich gedacht aber so ein Einbruch nicht.

[Lucky72]

Antwort auf Beitrag Nr.: 37.965.710 von Sundaysdinner am 11.09.09 20:46:57

Heute ist Freitag und die Amis nehmen ihre Gewinne mit!

Montag gehts wieder UUUUPPPP!

[Sundaysdinner]

Antwort auf Beitrag Nr.: 37.965.739 von Lucky72 am 11.09.09 20:53:10

Zu wünschen wäre es, aussehen tut es dennoch nicht so,bin noch zu unentschlossen hätte mir heute auch einen Normalen Anstieg gewünscht trotz Freitag.

Noch kein Kaufsignal für mich, erster Run ist ja eh schon durch, und das aus dem letztem Jahr sowieso

[Lucky72]

Antwort auf Beitrag Nr.: 37.965.785 von Sundaysdinner am 11.09.09 21:00:25

Jetzt kommt die "Hour of Power"!

Vielleicht dreht der Kurs noch!

[Lucky72]

Dynavax trials hepatitis B vaccine

Friday 11th September 2009

US biopharmaceutical company Dynavax is planning a phase III trial of its Heplisav adult hepatitis B vaccine in chronic kidney-disease patients.

The new drug is designed to provide increased and rapid protection with fewer doses than current licensed alternatives.

Dynavax has worldwide commercial rights to Heplisav, which combines hepatitis B surface antigen (HBsAg) with a proprietary Toll-like Receptor 9 (TLR9) agonist to enhance the immune response.

The company reports that 2,500 people have been vaccinated with Heplisav to date. Data from PHAST clinical trials reportedly show a seroprotection rate of 92%, compared to 75% of subjects receiving 3 doses of a licensed vaccine over six month

Says Dynavax boss Dino Dina: "The success of our scientific approach to resolving the clinical hold on Heplisav allows us to resume development of our hepatitis B vaccine.

"After achieving strong efficacy data in our prior phase 3 pivotal trial, we are fully prepared to initiate the final registration trials for Heplisav.

http://www.pharmacyeurope.net/default.asp?title=Dynavaxtrial…

[zpo]

Antwort auf Beitrag Nr.: 37.965.833 von Lucky72 am 11.09.09 21:10:02

.

Jetzt beginnt die power-hour

.

[Lucky72]

Antwort auf Beitrag Nr.: 37.965.969 von zpo am 11.09.09 21:31:57

Sieht gut aus!

Dann kanns am Montag weiter UP gehn!

[Lucky72]

After Hours: 2.25$ Up 0.03 (1.35%) 7:50PM ET

[Lucky72]

Nanu, keiner mehr da?

[Sundaysdinner]

Antwort auf Beitrag Nr.: 37.977.264 von Lucky72 am 14.09.09 19:54:30

Doch schon, aber was soll man den schreiben bei der Tal fahrt, immer noch kein Zeitpunkt zum einsteigen

Besserung ist noch nicht in Sicht, fast der Komplette Hype wieder auf Start

[Lucky72]

Antwort auf Beitrag Nr.: 37.977.732 von Sundaysdinner am 14.09.09 21:02:04

WOW! Der Kurs ist in USA wieder um 2,70% abgekackt!

[Sundaysdinner]

Antwort auf Beitrag Nr.: 37.978.315 von Lucky72 am 14.09.09 22:18:13

Sorry wenn ich dich belustige, aber von 2,20€ auf 1,40€ sind für mich keine 2,7%, und in gut 4 tagen kein Aufwärtstrend, auch das ist für die jenigen die im Hype aufgesprungen sind nicht Lustig.

[Lucky72]

Antwort auf Beitrag Nr.: 37.980.226 von Sundaysdinner am 15.09.09 10:42:59

Keine Panik es geht wieder UUUPPPP!

[Lucky72]

Sehn wir heute noch die 3$??

[Lucky72]

Dynavax ist nix für schwache Nerven!!

[Sundaysdinner]

Antwort auf Beitrag Nr.: 37.985.040 von Lucky72 am 15.09.09 19:22:41

Schön, hoffe es geht noch über die 4$!, bin nicht dabei musste mich zwischen hier und Cel-Sci Corp entscheiden und denke, bin gut damit gefahren.

Eventuell morgen mal was von den gewinnen dort hier Postieren, schauen wir mal.

[Lucky72]

Antwort auf Beitrag Nr.: 37.985.519 von Sundaysdinner am 15.09.09 20:16:29

Glückwunsch, da hattest du den richtigen Richer!

[Sundaysdinner]

Antwort auf Beitrag Nr.: 37.985.547 von Lucky72 am 15.09.09 20:19:19

Danke, aber den Zwiespalt kannst du dir ja ungefähr vorstellen, hier oder dort echt übel, mein Magen drückt immer noch hätte auch nach hinten losgehen können.

Nicht jeder Tag ist SUNDAYSDINNER

[Lucky72]

Antwort auf Beitrag Nr.: 37.985.681 von Sundaysdinner am 15.09.09 20:34:23

Nicht jeder Tag ist SUNDAYSDINNER

Nicht jeder Tag ist "Lucky"!

[Lucky72]

Detailed Quote for Dynavax Technologies Corp. (DVAX)
$ 2.18 0.02 (+0.93%) Volume: 2.64 m 16:00 EDT 15.09.2009

[Elmshorner]

Kursziel 10 Dollar...das ist noch ein langer Weg.

[Lucky72]

Antwort auf Beitrag Nr.: 37.994.204 von Elmshorner am 16.09.09 19:26:58

Macht nix! Ich hab Zeit!

[Lucky72]

Wie ein Fels in der Brandung!

[Lucky72]

Langweilig! Ohne News geht hier garnix!

[Lucky72]

Die Ruhe vor dem Sturm???

[Lucky72]

Filed pursuant to Rule 424(b)(3)

Registration No. 333-139664

Prospectus

$100,000,000



Common Stock

We may offer and sell from time to time shares of our common stock in one or more offerings in amounts, at prices and on the terms that we will determine at the time of offering, with an aggregate initial offering price of up to $100,000,000. Upon the commencement of any offering of common stock, we will provide specific terms of the offering in a supplement to this prospectus. The prospectus supplement also may add, update or change information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement, as well as any documents incorporated by reference in this prospectus and any prospectus supplement, carefully before you invest in any securities. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement.

We will sell these securities directly to our stockholders or to purchasers or through agents on our behalf or through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions or discounts.

Our common stock trades on The NASDAQ Capital Market under the trading symbol “DVAX.” On September 16, 2009, the last reported sale price of our common stock was $2.12 per share. As of September 16, 2009, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $82,506,806 based on 39,993,170 shares of outstanding common stock, of which approximately 38,917,965 shares were held by non-affiliates, and a per share price of $2.12 based on the closing sale price of our common stock on September 16, 2009. We recommend that you obtain current market quotations for our common stock prior to making an investment decision.

Investing in our securities involve a high degree of risk. See “Risk Factors” beginning on page 5 of this prospectus and the risk factors contained in our filings with the Securities and Exchange Commission which have been incorporated herein by reference.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is September 17, 2009.

http://ih.advfn.com/p.php?pid=nmona&cb=1253259521&article=39…

[Lucky72]

Bid: 1.95$
Ask: 2.08$

[Lucky72]

Verdächtig ruhig bei den Amis!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.009.996 von Lucky72 am 18.09.09 15:04:10

was hast Du erwartet?

[Lucky72]

Antwort auf Beitrag Nr.: 38.010.039 von Elmshorner am 18.09.09 15:09:14

Einen Kurs von 5$

[Lucky72]

[Lucky72]

Ist das Gap endlich geschlossen?

[Elmshorner]

Antwort auf Beitrag Nr.: 38.010.132 von Lucky72 am 18.09.09 15:18:39

ich auch...das dauert wohl noch etwas.

[Elmshorner]

Antwort auf Beitrag Nr.: 38.010.635 von Lucky72 am 18.09.09 15:59:31

Wenn ich das Orderbuch sehe, müsste es heute geschlossen sein.

[Lucky72]

Antwort auf Beitrag Nr.: 38.011.254 von Elmshorner am 18.09.09 16:50:49

Danke für die Info!

Dann kanns jetzt wieder UUUPPPPP gehn!

[Lucky72]

Es geht wieder hoch!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.012.753 von Lucky72 am 18.09.09 19:48:53

Wenn mich nicht alles täuscht, dann wird es heute nach 6 Tagen mal wieder grün.

[Lucky72]

Antwort auf Beitrag Nr.: 38.012.761 von Elmshorner am 18.09.09 19:50:03

Wir haben noch zwei Stunden Zeit!
Vielleicht wirds ja "Dunkelgrün"

[Lucky72]

Aus dem Yahoo!

Re: $100 mln shelf filed yesterday - 8 minutes ago
They will definitely be offering that amount in installment, over probably next year or two.

However, based on the price movement lately, they will be offering the first installment to set a base for new institutional investors to get in.

One must understand that such capital raising is not decided by the company, but rather, it's underwriter(s) who make the call, b/c the underwriters will be the ones to come up with the money. Therefore, the first installment has to be at the basement price - big investors need incentives to put up the money.

The h-b vaccine could be a blockbuster seller globally, b/c the vaccine is very different from the traditional vaccines in use already. It would provide rapid build up in immunity, and it would be the first of its kind. Phase 3 trial is the best starting point for new investors.

http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_D/t…

[Lucky72]

Time & Sales
Price Size Exch Time
1.97 400 NGS 16:03:15
2.00 100 BATS 16:00:14
2.00 100 BATS 16:00:14
2.02 100 NGS 16:00:11
2.00 100 NDD 16:00:11
2.02 100 NGS 16:00:10
2.00 100 NDD 16:00:09
2.00 200 NDD 16:00:07
2.08 200 BATS 16:00:07
1.98 127857 NGS 16:00:01
1.97 200 ISE 15:59:59

[Sundaysdinner]

Wann ist Schluss mit der Reise in den Süden?, Story ist doch gut sind die Ami's wieder zu blöd?

Jeden Tag verschiebe ich schon den einstieg, denk mal das wird nix mehr hier (für mich).

[Lucky72]

Antwort auf Beitrag Nr.: 38.015.705 von Sundaysdinner am 19.09.09 16:56:06

Der Chart sieht nicht schlecht aus!

Wie hoch wirds wohl gehn????

[Sundaysdinner]

Antwort auf Beitrag Nr.: 38.016.357 von Lucky72 am 19.09.09 20:47:35

Wenn Du mir da mal eine 100% aussage zu machen würdest, könnte ich mich übereden lassen auch einzusteigen

[Lucky72]

Antwort auf Beitrag Nr.: 38.018.029 von Sundaysdinner am 20.09.09 17:23:47

Ich will dich zu nichts überreden!

Kannst ja hier nachlesen
http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_D/m…
und dir deine eigene Meinung bilden!

[Lucky72]

http://www.americanbulls.com/StockPage.asp?CompanyTicker=DVA…

[Lucky72]

ES GEHT UUUUUUUPPPPPPPP!!!!!

[Lucky72]

Heute noch 2,20$?

[Lucky72]

Dynavax Announces HEPLISAVTM Data to Be Presented at IDSA Medical Conference
Date : 09/22/2009 @ 6:45AM
Source : Business Wire
Stock : Dynavax Technologies Corporation (DVAX)
Quote : 2.0504 -0.0996 (-4.63%) @ 7:22AM




Dynavax Announces HEPLISAVTM Data to Be Presented at IDSA Medical Conference

Dynavax Technologies Corporation (NasdaqVAX) today announced that an abstract with chronic kidney disease patient data for HEPLISAVTM, an investigational adult hepatitis B vaccine, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania, from October 29 through November 1, 2009.

For more information on this conference, please visit the IDSA website at http://www.idsociety.org.

About HEPLISAV

HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines. Over 2,500 individuals have been vaccinated with HEPLISAV to date. Dynavax is developing HEPLISAV for populations that are less responsive to current licensed vaccines, including adults over 40 years of age, individuals with chronic kidney disease, and others.

Dynavax has worldwide commercial rights to HEPLISAV, which combines hepatitis B surface antigen (HBsAg) with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

http://ih.advfn.com/p.php?pid=nmona&cb=1253645531&article=39…

[Lucky72]

Die News auf "googlisch"

http://translate.google.de/translate?hl=de&sl=en&u=http://in…

[Lucky72]

Ich hab Zeit!

[Lucky72]

Ich hoffe das die 1,85$ halten!

[Lucky72]

"Punktlandung"

Ab jetzt gehts hoffentlich wieder UP

[Lucky72]

Hat jemand aktuelle Zahlen?

http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

Bei Glaxo tut sich was!

http://www.cnbc.com/id/33052575

[Lucky72]

Antwort auf Beitrag Nr.: 38.067.516 von Lucky72 am 28.09.09 10:27:40

Glaxo, Brazil Sign $1 Billion Vaccine Deal: Report
Published: Monday, 28 Sep 2009 | 1:26 AM ET
Text Size
By: Reuters

GlaxoSmithKline [GSK 39.25 0.32 (+0.82%) ] has sealed a 1.5 billion euro (1 billion dollar) deal with Brazil, guaranteeing sales of its pneumococcal vaccine over the entire life of the product, the Financial Times said on Monday.

GSK will receive a starting price for the vaccine, aimed at preventing pneumonia and meningitis, of 11.50 euros, and falling to 5 euros in future years, the newspaper said.

The deal is seen as a landmark as most drugs are sold over far shorter periods and have a more uncertain pricing structure, the FT added. They also face competition from lower-cost rivals.

GSK said earlier this month it was forming a partnership with Brazil's Fiocruz over the development of the Synflorix vaccine.

[Lucky72]

Ich glaube die \"Mffaisseite\" braucht einen Update!

http://www.mffais.com/dvax

Nur zur Info!

http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

Die Ruhe vor dem Sturm?!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.072.524 von Lucky72 am 28.09.09 21:00:46

es kann auch nicht immer nur runter gehen

[Elmshorner]

....es sieht heute nach dunkelgrün aus

[Elmshorner]

Dynavax Initiates Phase 3 Registration Trial in Chronic Kidney Disease Patients for HEPLISAVTM Hepatitis B Vaccine
Press Release
Source: Dynavax Technologies Corporation
On Tuesday September 29, 2009, 6:45 am EDT

Companiesynavax Technologies Corporation
BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (NasdaqVAX - News) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines. Dynavax believes that these studies, taken together, could support registration filing of HEPLISAV with the Food and Drug Administration (FDA).

“After achieving pivotal trial data demonstrating HEPLISAV’s clinical benefit, we currently expect to complete these two registration trials within the next 24 months,” commented Dino Dina, M.D., President and Chief Executive Officer of Dynavax. “The unmet medical need for better hepatitis B vaccination for certain groups such as chronic kidney disease patients is significant and is a large, servable market opportunity for Dynavax.”

About the Trial

Dynavax’s Phase 3 trial is enrolling approximately 600 patients with chronic kidney disease. After being randomized 1 to 1, patients will receive either 3 doses of HEPLISAV (at 0, 1, and 6 months) or 8 doses of the current licensed vaccine Engerix-B® (2 doses at 0, 1, 2, and 6 months). The primary endpoint is seroprotection rate at month 7.

Clinical Data

Dynavax plans to present clinical data from previous trials of HEPLISAV in chronic kidney disease patients at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA), October 29 through November 1, 2009 in Philadelphia, Pennsylvania. For more information on this conference, please visit the IDSA website at http://www.idsociety.org.

[Lucky72]

Antwort auf Beitrag Nr.: 38.076.023 von Elmshorner am 29.09.09 13:01:18

Auf was warten die Amis!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.080.758 von Lucky72 am 29.09.09 20:59:09

...das ist mir ein Rätsel

[Elmshorner]

Mit wenig Volumen wird der Kurs gedrückt

[Lucky72]

Antwort auf Beitrag Nr.: 38.096.856 von Elmshorner am 01.10.09 17:53:37

Mit Miniposis wird hier der Kurs gedrückt!

[Lucky72]

Vielleicht sammelt einer!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.098.374 von Lucky72 am 01.10.09 20:29:40

So sieht es aus....es wird bald nach Norden gehen

[Lucky72]

Short Interest
Date Short Interest % Change Avg. Daily Share

Sept 15, 2009 650,387 290.38 4,341,821 1.00 No No
Aug 31, 2009 166,602 -53.63 436,230 1.00 No No
Aug 14, 2009 359,316 115.39 821,178 1.00 No No
Jul 31, 2009 166,818 -37.14 736,666 1.00 No No
Jul 15, 2009 265,384 -0.43 168,692 1.57 No No
Jun 30, 2009 266,542 -20.98 361,028 1.00 No No
Jun 15, 2009 337,324 237.36 1,682,140 1.00 No No
May 29, 2009 99,990 50.55 539,761 1.00 No No
May 15, 2009 66,418 -31.36 423,183 1.00 No No
Apr 30, 2009 96,756 37.90 703,385 1.00 No No

http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DVAX#g…

[Lucky72]

Antwort auf Beitrag Nr.: 38.110.644 von Lucky72 am 04.10.09 09:19:11

Der Hype war am 10.9.09!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

Wird Zeit das hier die Shorty gegrillt werden!

[Lucky72]

Flieg meine Perle! Flieg auf 5$!!!

[Lucky72]

Ich wette mein linkes Ei das wir bis zu 29.10.09 wieder bei 3USD stehn!

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=410…

PS: Das mit dem "Ei" war nur Spaß!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.119.548 von Lucky72 am 05.10.09 22:44:21

5 Dollar ist mein Kursziel

[Lucky72]

Das ist ja ein lausiges Volumen!

[Lucky72]

[Lucky72]

Antwort auf Beitrag Nr.: 38.121.381 von Elmshorner am 06.10.09 11:11:47

Mein KZ liegt bei 8$

[Lucky72]

Gibts hier eigentlich Zahlen für das 2Q 2009?
Ich kann nix finden!

[Lucky72]

Antwort auf Beitrag Nr.: 38.127.166 von Lucky72 am 06.10.09 21:00:34

Jetzt hab ich sie doch gefunden!

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=67356…

[Sundaysdinner]

Nabend, hab ich was verpasst? kein Handel in DE ?

[Elmshorner]

Im Ami-Land wird gedrückt ohne Ende

[Lucky72]

Noch drei Wochen dann brennt hier die Luft!

[Lucky72]

News are in the pipe!

[Lucky72]

Guten Morgen

[Lucky72]

Gibts schon News?

[Lucky72]

Der Kursverlauf und das Volumen waren nicht schlecht für einen Freitag!
Ich denke das hier bald was kommt!

[Lucky72]

Antwort auf Beitrag Nr.: 38.142.664 von Elmshorner am 08.10.09 19:16:13

Das sehe ich auch so!

Wird Zeit das wir die Shorty grillen

Nur zur Info

Sunday October 11, 2009
Short Quote™

Dynavax Technologies Corp.
Short Interest (Shares Short) 752,800

[Lucky72]

Antwort auf Beitrag Nr.: 38.154.439 von Lucky72 am 11.10.09 10:30:21

Zum vergleich

Short Interest - Prior 650,400

[Lucky72]

Hier ist der Link!

http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

Was bedeutet das??

Merger and Acquisition Scenario
GlaxoSmithKline plc (ADR) (GSK) and Dynavax Technologies Corporation (DVAX)

http://www.reveredata.com/reports/store/report/mna/4490_2390…

[Lucky72]

Die Drückerkolonne ist wieder am Werk!

[Lucky72]

Date Short Interest

Sept 30, 2009 752,837
Sept 15, 2009 650,387
Aug 31, 2009 166,602
Aug 14, 2009 359,316
Jul 31, 2009 166,818
Jul 15, 2009 265,384
Jun 30, 2009 266,542
Jun 15, 2009 337,324
May 29, 2009 99,990
May 15, 2009 66,418

[Lucky72]

Will da jemand rein?
Bid: 1.78 x 69400
Ask: 1.79 x 3600

[Elmshorner]

Antwort auf Beitrag Nr.: 38.162.054 von Lucky72 am 12.10.09 20:24:38

Als Leerverkäufer kann man sich hier schnell die Finger verbrennen

[Lucky72]

Antwort auf Beitrag Nr.: 38.164.684 von Elmshorner am 13.10.09 10:38:23

Lausiges Volumen!

Auf was warten die Burgerfresser!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.169.883 von Lucky72 am 13.10.09 20:04:07

Sie pokern bis hier Volumen reinkommt...dann geht es ab

[Elmshorner]

Läuft der Rebound an?

[Elmshorner]

....die Burgerfresser kaufen

[Lucky72]

Antwort auf Beitrag Nr.: 38.177.841 von Elmshorner am 14.10.09 18:22:30

Zeit wirds!

[Lucky72]

Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak
Date : 10/14/2009 @ 11:06AM
Source : PR Newswire
Stock : (DVAX)
Quote : 1.76 0.07 (4.14%) @ 7:22AM




Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak

PRINCETON, N.J., Oct. 14 /PRNewswire/ -- Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in the connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for Gilead Sciences (NASDAQ:GILD), Sinovac Biotech (AMEX:SVA), Dynavax Technologies (NASDAQVAX), Hemispherx BioPharma (AMEX:HEB), BioCryst Pharmaceuticals (NASDAQ:BCRX) and several others.

After posting large gains throughout 2009, swine flu stocks are seeing their largest pullback yet. For investors looking to position their portfolios for flu season, there are more ways to trade the flu than ever. Investors have large-cap pharmaceutical plays to choose from, and some of the more volatile, small-cap names have proven the efficacy of their drugs, while others are too far behind in their clinical trials to capitalize on the current pandemic.

To receive a free, 23-page report offering in depth analysis of the various participants in the vaccine and antiviral market, as well as some peripheral plays focusing directly on the impact of the current H1N1 swine flu pandemic, please visit the following link:

http://www.bullmarket.com/digest/signup.php?refer=pr1_swineflu" target="_blank" rel="nofollow ugc noopener">http://www.bullmarket.com/digest/signup.php?refer=pr1_swineflu

The report covers these topics and more recent reports:

-- Which small-cap swine flu plays have a real chance of benefiting in the event of a serious H1N1 outbreak and which are riding on the hype?

-- What sets Sinovac apart from other small caps pursuing vaccines and treatments to fight swine flu? How robust is Sinovac's array of products?

-- Is BioCryst likely to see revenue from its flu treatment during this flu season? How does BioCryst's peramivir fare against established drugs Tamiflu and Relenza? What are the downside risks facing BioCryst after its strong run higher?

-- Is Dynavax a real swine flu play? What do Dynavax investors need to know about the company's swine flu efforts?

-- How important is Tamiflu to Gilead's business? What are the mechanics of Gilead's Tamiflu royalty arrangement with Roche? What are the threats to Tamiflu's dominance in the antiviral market?

About Weekly Digest:

Weekly Digest is a free publication offering first-rate stock research, analysis, and commentary that is independently published by leading investment services. Subscribers receive a weekly newsletter as well as regular Special Reports, such as the new report Investor Essentials: Picking Winners for Pandemic Profits.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, [phone]

DATASOURCE: Indie Research Advisors, LLC

CONTACT: Marcia Martin, [phone]

Web Site: http://www.bullmarket.com/digest

http://ih.advfn.com/p.php?pid=nmona&cb=1255537874&article=39…

[Elmshorner]

Antwort auf Beitrag Nr.: 38.177.938 von Lucky72 am 14.10.09 18:34:10

5 Dollar will ich sehen

[Lucky72]

Antwort auf Beitrag Nr.: 38.178.133 von Elmshorner am 14.10.09 18:57:26

Aber nich bei dem Volumen!

Ich bin vor langeweile schon eingenickt!

[Lucky72]

[Lucky72]

WOW! Ganz schön mutig!
Times & Sales (Frankfurt)
Zeit Kurs Stück
19:48:49 1,22 200

[Lucky72]

Sehn wir heute noch die 2$?

[Lucky72]

Naja, fast hätte es geklappt!

[Lucky72]

Time & Sales
Price Size Exch Time
t 1.88 2200 NYE 19:44:14
t 1.90 900 ISE 19:36:32
t 1.88 200 NYE 19:36:32
t 1.88 1600 NYE 19:36:31
t 1.88 900 NYE 19:30:45
1.87 200 NDD 19:29:43
t 1.87 1000 NYE 19:28:31
1.85 1030 NDD 19:28:30
1.85 200 NGS 19:28:30
1.83 600 NDD 19:27:33
1.83 2000 NDD 19:26:21
t 1.83 100 ISE 18:37:38
t 1.82 900 ISE 18:37:32
1.82 1000 NDD 18:31:55
1.82 100 NDD 18:06:17
1.81 100 NGS 17:40:47

http://www.otcbb.com/asp/Info_Center.asp

[Lucky72]

Die Amis haben gleich ihre Burger verdrückt, dann kommt wieder Bewegung rein!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.186.945 von Lucky72 am 15.10.09 18:43:04

Spottbillig ist das Teil

[Lucky72]

Antwort auf Beitrag Nr.: 38.187.486 von Elmshorner am 15.10.09 19:43:12

Die Amis sind wohl anderer Meinung!

[Elmshorner]

Das wird heute noch grün

[Lucky72]

Antwort auf Beitrag Nr.: 38.187.610 von Elmshorner am 15.10.09 19:55:52

Das denke ich auch!

Gestern waren wir Nachbörslich auch bei 1,90$

[Lucky72]

BUYINS.NET: 50.27% Of All NASDAQ Trading Wednesday Was Short Selling. OESX, BNVI, DVAX, TBNK, AMCN, BJRI Highest % Of Daily Trading Volume Short

Oct 15, 2009 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Wednesday, October 14th, 2009 and come to the following statistical conclusions. There were 6,838 stocks with daily short volume reported and total NASDAQ trading volume of 1,884,440,575 shares. Total Daily Short Volume was 947,410,475 shares. 50.27% of all trading on the NASDAQ Wednesday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. Orion Energy Systems (NASDAQ: OESX), Bionovo (NASDAQ: BNVI), Dynavax Technologies (NASDAQ: DVAX), Territorial Bancorp (NASDAQ: TBNK), AirMedia Group (NASDAQ: AMCN) and BJs Restaurants (NASDAQ: BJRI). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20091014 OESX 248,763 259,310 Q 95.93%

20091014 BNVI 155,426 181,700 Q 85.54%

20091014 DVAX 94,672 111,547 Q 84.87%

20091014 TBNK 68,700 85,109 Q 80.72%

20091014 AMCN 122,525 152,755 Q 80.21%

20091014 BJRI 209,728 261,502 Q 80.20%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

[Lucky72]

Antwort auf Beitrag Nr.: 38.187.978 von Lucky72 am 15.10.09 20:40:17

Hier ist der Link!
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DVAX#g…" target="_blank" rel="nofollow ugc noopener">
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DVAX#g…

[Elmshorner]

Antwort auf Beitrag Nr.: 38.188.013 von Lucky72 am 15.10.09 20:44:50

Die 2 Dollar lassen auf sich warten...

[Lucky72]

Antwort auf Beitrag Nr.: 38.193.975 von Elmshorner am 16.10.09 15:25:24

Schön langsam dürften die Burgerboys in die Puschen kommen!

[Lucky72]

Guten Morgen!

Noch 10 Tage bis zur "IDSA Medical Conference"

[Lucky72]

Langsam kommt Bewegung rein!

[Lucky72]

Es gibt News!!

20.10.2009 12:46
Dynavax to Present at the Oppenheimer Healthcare Conference

Dynavax Technologies Corporation (NASDAQVAX) announced today that it plans to present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009 at 10:15 am EST (7:15 am PST) at the Waldorf Astoria Hotel in New York.

Dino Dina, M.D., President and Chief Executive Officer of Dynavax, will provide a corporate overview presentation. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax’s website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Contacts:

Dynavax Technologies Corporation
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
[e-mail]

http://www.finanznachrichten.de/nachrichten-2009-10/15241598…

[Lucky72]

Oppenheim hat 88.1K Aktien verkauft!

Aber die brauchen ja dringend Geld!

Quelle: http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

Jetzt zieh schon!!

[Lucky72]

WOW! Es wird abgeladen aber der Kurs hält!

[Lucky72]

Dynavax to Report Third Quarter 2009 Financial Results after Market Closes on October 22, 2009
Date : 10/21/2009 @ 4:36PM
Source : Business Wire
Stock : Dynavax Technologies Corporation (DVAX)
Quote : 1.69 0.07 (4.32%) @ 7:22AM




Dynavax to Report Third Quarter 2009 Financial Results after Market Closes on October 22, 2009

Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to report third quarter 2009 financial results after the market closes on Thursday, October 22, 2009.

The Company also plans to host a webcast of a conference call on Thursday, October 22, 2009 at 4:30 pm EDT (1:30 pm PDT). To access the live audio webcast and the subsequent archived audio recording of the presentation, please log onto Dynavax’s website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.


http://ih.advfn.com/p.php?pid=nmona&cb=1256157547&article=40…

[Lucky72]

Heute gibts Shorty vom Grill!

[Lucky72]

[Lucky72]

Lausiges Volumen!

Auf was warten die Burgerboys?

[Lucky72]

Das ist zum ko...!

Mit Miniposis wird hier der Kurs gedrückt!

[Lucky72]

Gehts endlich los?

[Lucky72]

http://ih.advfn.com/p.php?pid=nmona&cb=1256242872&article=40…

[Lucky72]

Nächsten Freitag wieder 2$?!

[Lucky72]

Na wenigstens können die Shorty billig covern!

[Sundaysdinner]

Lucky lucky Lucky, bist hier ganz alleine was Kurse zum einsteigen seit 1 Monat nicht gegeben

trau mich schon gar nicht mehr rein zuschauen, hoffe Du bist zu niedrigen Kursen hier dabei!

[Lucky72]

Antwort auf Beitrag Nr.: 38.244.596 von Sundaysdinner am 23.10.09 21:25:58

Zeit zum Einsteigen oder Nachlegen?!

[Lucky72]

Oder werden die US Boys den Kurs weiter in die Tonne treten?

[Lucky72]

Totenstille in den US Boards!

[Lucky72]

[Lucky72]

Stahlhelm aufsetzen und nachladen!

[Lucky72]

BUYINS.NET: Dynavax Technologies (DVAX) Daily Short Sale Trading Volume Through 10-23-09

Oct 26, 2009 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report through Friday, October 23rd, 2009 and come to the following statistical conclusions. The chart below shows aggregated daily short volume in Dynavax Technologies (NASDAQ: DVAX) for August through October 23rd, 2009. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

Date Short Volume Total Volume Percent

10/23/2009 198,561 2,332,700 8.51%

10/22/2009 58,241 369,000 15.78%

10/21/2009 107,019 525,000 20.38%

10/20/2009 74,486 469,600 15.86%

10/19/2009 23,046 235,200 9.80%

10/16/2009 48,565 377,500 12.86%

10/15/2009 35,311 264,600 13.35%

10/14/2009 121,033 570,100 21.23%

10/13/2009 35,203 374,100 9.41%

10/12/2009 136,127 788,400 17.27%

10/9/2009 157,614 1,110,100 14.20%

10/8/2009 38,199 311,600 12.26%

10/7/2009 33,121 365,800 9.05%

10/6/2009 31,112 430,900 7.22%

10/5/2009 103,286 771,100 13.39%

10/2/2009 62,121 564,700 11.00%

10/1/2009 151,666 1,106,500 13.71%

Total 9,313,124 81,194,786 11.47%

* Daily Short Volume chart has been truncated for viewing purposes. Totals include short volumes starting August 3, 2009 and through yesterdays close.

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchanges naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of Toll-like Receptor (TLR) product candidates primarily in the United States. Based on Dynavaxas proprietary technology platform, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. The companyas product programs are supported by global partnerships with pharmaceutical companies, such as GlaxoSmithKline, AstraZeneca AB, and Novartis Vaccines and Diagnostics, Inc, as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health (NIH). Its product candidates include HEPLISAV, a Phase 3 clinical stage product for the treatment of hepatitis B vaccine; SD-101, a Phase 1b clinical stage product for the treatment of Hepatitis C infection; and DV-601, a Phase 1b clinical stage product for the treatment of Hepatitis B infection. Dynavax Technologies Corporationas preclinical stage products include Universal Flu vaccine for the treatment of influenza prevention, AZD1419 for the treatment of asthma, and DV1079 for the treatment of autoimmune and inflammatory diseases. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

Quelle http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DVAX#g…

[Lucky72]

Wann platzt die Bombe?

Dynavax Technologies Corp.

$ 1.30
DVAX
-0.09
Short Interest (Shares Short)
1,062,900
Days To Cover (Short Interest Ratio)
1.7
Short Percent of Float
6.39 %
Short Interest - Prior
752,800
Short % Increase / Decrease
41.19 %
Short Squeeze Ranking™
40

http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[roofy]

hmmm
das sieht doch jetzt ganz interessant aus

[Lucky72]

Am Donnerstag beginnt die IDSA Medical Conference!

[Lucky72]

Brenn Shorty brenn!!!!

[Lucky72]

Ohne Worte!

[Lucky72]

Kann bitte jemand die Schlussglocke läuten!

[Lucky72]

Bin schon gespannt ob es am Montag ein Monstergap gibt!

[Lucky72]

Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients

First HEPLISAV Chronic Kidney Disease Data to be Presented at IDSA

BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (Nasdaq: DVAX - News) today announced the first clinical data for HEPLISAVTM investigational hepatitis B vaccine in chronic kidney disease patients. These data will be presented in a poster session on Saturday, October 31, 2009 at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania.

Vaccinated with HEPLISAV, chronic kidney disease patients demonstrated rapid, increased protection against hepatitis B viral infection in fewer doses than patients receiving licensed vaccine. 96% of patients (n = 36) receiving 3 doses of HEPLISAV achieved seroprotection at month 7, compared to 88% of patients (n = 10) receiving 8 doses of Engerix-B®. Dynavax recently began vaccinating chronic kidney disease patients with HEPLISAV in a Phase 3 registration trial.

“For chronic kidney disease patients at increased risk of exposure to hepatitis B viral infection, achieving rapid and efficacious protection is critical," commented Shelly McNeil, M.D., Canadian Center for Vaccinology, Halifax, Nova Scotia and Principal Investigator. "A vaccine that provides faster, superior immunogenicity with a more convenient dosing regimen could offer significant clinical benefits for hyporesponsive chronic kidney disease patients and the dialysis centers that routinely immunize these patients."

HEPLISAV Chronic Kidney Disease Data

Two single-blind, randomized, multi-center studies were conducted in 87 chronic kidney disease patients. In both studies, HEPLISAV was safe and well tolerated.

* In the first trial, 46 patients were randomized to receive 3 doses of HEPLISAV (HBsAg-ISS), administered at 0, 1, and 6 months, or 8 doses of Engerix-B licensed vaccine, administered at 0, 1, 2, and 6 months.
* In the second trial, 41 patients were enrolled to receive 3 doses of HEPLISAV, administered at 0, 1 and 6 months. This trial was halted after patients received two doses of HEPLISAV.

In the first trial, seroprotection rates were higher and achieved earlier for patients receiving HEPLISAV than for patients receiving Engerix-B.

In the second trial, seroprotection rates were 10% post first immunization, 59% post second immunization, and 100% at month 6 without any additional immunizations. Complete data from this second trial will be presented at a future medical conference.

At all time points, consistently higher geometric mean concentration (GMCs) of anti-HBsAg were observed in the HEPLISAV groups compared to the Engerix-B group. In the chronic kidney disease patient population, higher anti-HBsAg titers are important in maintaining seroprotection for a longer period of time.

In the first trial in 46 subjects, GMCs were as follows:

* Measured 1 month after the last dose of vaccine, 89% of patients receiving HEPLISAV achieved anti-HBsAg titers above 100 mIU/mL, compared to 63% of patients receiving Engerix-B.
* Measured 6 months after the last dose of vaccine, 86% of patients receiving HEPLISAV maintained anti-HBsAg titers above 100 mIU/mL, compared to 33% of patients receiving Engerix-B.

For a copy of the poster presentation, please visit http://investors.dynavax.com/newsevents.cfm.

About HEPLISAV

HEPLISAV is a Phase 3 adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines. Over 2,500 individuals have been vaccinated with HEPLISAV, which has completed a pivotal Phase 3 study demonstrating the vaccine’s immunogenicity.

Dynavax is developing HEPLISAV for populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. The Company has worldwide commercial rights to HEPLISAV, which combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist referred to as ISS to enhance the immune response.

About Hepatitis B Vaccines

The total worldwide market for adult hepatitis B vaccines is estimated at over $500 million annually. Current vaccines leave unmet needs for more rapid and increased protection, particularly for less responsive, underserved populations.

Chronic Kidney Disease Market – A high-value segment, the chronic kidney disease market is large, growing rapidly, and is widely recommended for vaccination. In 2006, there were approximately 750,000 end-stage renal disease (ESRD) patients in the United States and the 5 major European markets and approximately 150,000 new patients annually. Approximately 35% of these immunocompromised ESRD patients do not respond to vaccination and 20% require boosters. As vaccination for these patients occurs regularly at dialysis centers, this is a highly concentrated, renewable market that can be served by cost-effective, targeted sales and distribution networks.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward Looking Statements

This press release contains “forward-looking statements,” that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development, whether the studies can support registration for commercialization of HEPLISAV, the potential size and value of the chronic kidney disease market addressable with HEPLISAV, the commercial potential for HEPLISAV, and the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the “Risk Factors” section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

http://finance.yahoo.com/news/Dynavaxs-HEPLISAV-Shows-bw-445…

[Lucky72]

Nachbörslich gehts schon UP!

Time & Sales
Price Size Exch Time
1.40 250 NGS 16:06:14
1.40 1250 NGS 16:06:13
1.41 1000 NDD 16:06:12
t 1.40 1200 NGS 16:04:47
t 1.40 100 NGS 16:04:33
1.40 300 NDD 16:04:12
t 1.40 500 NYE 16:04:12
1.40 700 NGS 16:04:12
t 1.40 500 NYE 16:03:47
t 1.40 500 NYE 16:03:47
t 1.40 500 NYE 16:03:22
t 1.40 2000 NYE 16:03:18
t 1.40 500 NYE 16:03:18
t 1.40 200 ISE 16:03:17
1.40 500 NYE 16:03:17
1.40 1800 NGS 16:03:17
t 1.40 200 NGS 16:01:22
t 1.40 2500 ISE 16:00:37
1.40 1000 NDD 16:00:36
t 1.40 1000 ISE 16:00:28
t 1.40 1000 ISE 16:00:15
t 1.40 1000 ISE 16:00:15
t 1.40 1000 ISE 16:00:15
t 1.40 1000 ISE 16:00:15
t 1.40 1000 ISE 16:00:15
t 1.39 1000 NDD 16:00:11
1.38 900 NDD 16:00:11
1.38 1000 NDD 16:00:11
1.38 1000 NDD 16:00:11

[Lucky72]

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=420…

[Lucky72]

Time & Sales
Price Size Exch Time
1.45 400 NDD 16:47:23
1.44 600 NGS 16:47:23
1.44 100 NGS 16:42:45

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag!

[Lucky72]

Ein Neueinsteiger!

CREF Social ...37.4K $48,182

http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

[Lucky72]

http://files.shareholder.com/downloads/DVAX/753965771x0x3274…

[Lucky72]

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=68622…

[Lucky72]

- Prospectus filed pursuant to Rule 424(b)(5) (424B5)
Date : 10/30/2009 @ 3:19PM
Source : Edgar (US Regulatory)
Stock : (DVAX)
Quote : 1.26 -0.04 (-3.08%) @ 7:22AM




- Prospectus filed pursuant to Rule 424(b)(5) (424B5)

Table of Contents

Filed pursuant to Rule 424(b)(5)

Registration File No.: 333-139664

PROSPECTUS SUPPLEMENT

(To Prospectus dated September 17, 2009)





LOGO

$12,200,000

Common Stock





On August 17, 2009, we entered into an equity distribution agreement with Wedbush Morgan Securities, Inc. (“Wedbush”) relating to shares of our common stock, par value $0.001 per share.

Under the equity distribution agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $15 million from time to time through Wedbush as our sales agent. During the period from August 17, 2009 through October 26, 2009, we sold through Wedbush as our sales agent an aggregate of 1,281,100 shares of common stock for net proceeds of $2.3 million after deducting commissions paid to Wedbush and offering expenses. As of October 26, 2009, we could offer and sell shares of our common stock having an aggregate offering price of up to an additional $12.2 million from time to time through Wedbush under the equity distribution agreement.

Sales of our common stock through Wedbush, if any, will be made by means of ordinary brokers’ transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Wedbush.

We will pay Wedbush a commission, or allow a discount, as the case may be, in each case equal to 4.0% of the gross sales prices of the shares sold through it as agent under the equity distribution agreement.

Under the equity distribution agreement, we may also sell shares of common stock to Wedbush, as principal for its own account, at a price to be agreed upon at the time of sale.

Our common stock is listed on The NASDAQ Capital Market under the symbol “DVAX.” On October 26, 2009, the last reported sale price of our common stock was $1.30 per share. Based on such last reported sale price, as of the date hereof the aggregate market value of our outstanding voting and nonvoting common equity held by non-affiliates as calculated pursuant to General Instruction I.B.6 of Form S-3 was $52.3 million. As of the date hereof, we have sold securities with an aggregate market value of $2.8 million pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.





Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-6 of this prospectus supplement and the risk factors contained in our filings with the Securities and Exchange Commission which have been incorporated herein.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.





Wedbush PacGrow Life Sciences

The date of this prospectus supplement is October 30, 2009.

http://ih.advfn.com/p.php?pid=nmona&cb=1256930895&article=40…

[Lucky72]

Guten Morgen

Keine News von der IDSA Medical Conference?!

[Lucky72]

Geht heute was?

Dynavax to Present at the Oppenheimer Healthcare Conference

BERKELEY, Calif., Oct 20, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQVAX) announced today that it plans to present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009 at 10:15 am EST (7:15 am PST) at the Waldorf Astoria Hotel in New York.

Dino Dina, M.D., President and Chief Executive Officer of Dynavax, will provide a corporate overview presentation. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax's website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

SOURCE: Dynavax Technologies Corporation

Dynavax Technologies Corporation
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
[e-mail]


http://investors.dynavax.com/releasedetail.cfm?ReleaseID=416…

[Lucky72]

Antwort auf Beitrag Nr.: 38.306.939 von Lucky72 am 03.11.09 08:21:18

Ich hoffe Dino läßt die Katze bald aus dem Sack!

[Lucky72]

Was für eine schei.. Aktie!

Der Kurs kennt wirklich nur eine Richtung!

[Lucky72]

Nicht schlecht!

Als kurz vor Dynavax zu MKT Vereinbarung mit GSK vor HEPLISAV vorbereitet
genehmigt bekommen!

Über 350 Millionen Menschen weltweit sind chronisch mit infizierten
HBV, die zu Leberzirrhose und Leberkrebs führen kann. Wir
Schätzung der weltweite Markt für HBV-Therapie ist über $ 1
Milliarden Euro jährlich.

Zur Zeit genehmigte HBV-Therapie besteht aus langen Behandlung mit
antivirale Medikamente oder Interferon-alpha. Diese Therapien führen können
erheblichen Nebenwirkungen führen können zum Widerstand, und nicht immer
Heilung HBV.

Unsere HBV-Therapie, in Kombination mit anderen antiviralen
Therapien, wird erwartet, dass eine starke Immunantwort gegen HBV induzieren
infizierten Zellen in der Leber zu beseitigen und HBV-Infektion kann ein Angebot
mehr wirksame therapeutische Option für chronisch infizierten Patienten.

Dynavax und GlaxoSmithKline haben sich zu einer weltweiten strategischen eingetragen
Allianz zu entdecken, zu entwickeln und zu vermarkten Roman TLR-Hemmer
für Erkrankungen wie Lupus, Psoriasis und rheumatoider Arthritis. Wir
wird die Forschungs-und frühen klinischen Entwicklung führen in bis zu vier
Programme und haben Anspruch auf künftige Entwicklungsmöglichkeiten und empfangen
Kommerzialisierung in einer Gesamthöhe von rund 200 Millionen Dollar pro
Programm. GSK können ihre ausschließliche Möglichkeit Gebrauch jede Lizenz
Programm bei Erreichen des Proof-of-concept oder früher auf bestimmte
Umstände. Nach der Ausübung seiner Option wird GSK durchzuführen
weitere Entwicklung und Vermarktung dieser Produkte. Wir werden
Tiered erhalten, bis zu zweistellige Lizenzgebühren für den Verkauf und haben
erhalten die Option, die gemeinsame Entwicklung und Zusammenarbeit zu fördern einem Produkt.

Human Virus Influenza ist eine akute Erkrankung der Atemwege mit hohem
Morbidität und Mortalität, die in jährlichen Epidemien kommt weltweit vor.
Derzeit gibt es schätzungsweise 30.000 bis 40.000 Influenza-assoziierte virale
Todesfälle pro Jahr in den Vereinigten Staaten, vor allem bei Personen über 65 Jahre
des Alters. Influenza-Pandemien selten auftreten, im Durchschnitt alle 30 bis
40 Jahre, aber die nächste Pandemie könnte in Millionen Todesfälle
weltweit. Analysten schätzen den aktuellen weltweiten Marktchancen
für die saisonale Influenza-Impfstoffen auf rund 3 Milliarden Dollar
jährlich.

Standard Grippeimpfstoffe können Schutz gegen die Influenza
Stämme voraussichtlich während einer Saison werden weit verbreitet. Die Wirksamkeit von
dieser Impfstoffe wird oft durch unvorhersehbare Änderungen in der verringerten
tatsächlichen Influenza-Stämme verursacht. Aktuelle Impfstoffe sind auch am wenigsten
wirksame Prävention bei denen, die die meisten, ältere Menschen und müssen
andere mit schwächeren Immunsystem. Pandemie-Impfung ist weiter
kompliziert durch die Notwendigkeit, große Mengen an Impfstoff produzieren in einem
kurzer Zeit.

Unsere Universal-Grippe-Impfstoff zum Schutz vor bieten
unterschiedliche Influenza-Stämmen, erhöhen die Wirksamkeit der herkömmlichen
Impfstoffe und möglicherweise eine niedrigere Dosierung des Impfstoffs in die Verlängerung
verfügbare Menge bei einer Pandemie.

Unsere Forschungs-und Entwicklungsprogramm wurde teilweise finanziert durch
Zuschüsse aus den National Institutes of Health (NIH). Dynavax hat
wurde ein weltweites Angebot und Optionsvertrag mit Novartis
Vaccines and Diagnostics, Inc. für unsere Universal-Grippe-Impfstoff-Programms.

http://finance.google.com/group/google.finance.665622/messag…

[Lucky72]

Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors

BERKELEY, Calif., Nov 05, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NasdaqVAX) announced today that Francis R. Cano, Ph.D. has been appointed to Dynavax's Board of Directors effective November 3, 2009.

"A recognized scientific leader in vaccines and infectious diseases, Francis brings unique expertise and broad experience in research, development, and commercialization to Dynavax," commented Arnold L. Oronsky, Ph.D., Chairman of the Board of Directors of Dynavax. "Francis will provide valuable perspective as Dynavax advances its plans for its Phase 3 hepatitis B vaccine and pipeline products."

Dr. Cano is President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business. Previously, Dr. Cano was President and Chief Operating Officer for Aviron, which was later acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline Biologicals, and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years, Dr. Cano worked with the Lederle Laboratories Division of American Cyanamid, most recently as Vice President and General Manager of the Biologicals unit.

He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John's University.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

SOURCE: Dynavax Technologies Corporation

Dynavax
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
[e-mail]

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=422…

[Lucky72]

WOW!

Fidelity Spartan hat sich weitere 175.6K ins Depot gelegt!

http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

[Lucky72]

Last Trade: 1.28
Trade Time: 3:19pm ET
Change: Up 0.06 (4.92%)
Prev Close: 1.22
Open: 1.22
Bid: 1.28 x 37600
Ask: 1.29 x 42600

[Lucky72]

Guten Morgen

[Lucky72]

Antwort auf Beitrag Nr.: 38.338.681 von Lucky72 am 06.11.09 20:06:29

Ein kleiner Tipp!

Einfach die Seite von CNBC http://data.cnbc.com/quotes/DVAX/tab/8 ausdrucken!
Dann sieht man die Veränderungen!

[Lucky72]

Weiß jemand wieviel Aktien short sind?

[Lucky72]

Auf der "MFFAIS" Seite tut sich auch was!

http://www.mffais.com/dvaX

[Lucky72]

Hier ist der Chart!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Mit Dynavax hab ich ja eine richtige Perle gefunden!

[Lucky72]

Ich halte die Aktie für total unterbewerte und hoffe das wir bis Freitag wieder die 2$ sehn!

Nur meine Meinung!

[Lucky72]

Ich muß jetzt los sonst gibts nix zu Essen!

Viele Grüße aus Bayern!

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag!

[Lucky72]

WOW! +14,10%in FFM

[Lucky72]

Wohin geht die Reise????

[Lucky72]

Leider noch keine News!

Die Amis schlafen noch!

[Lucky72]

Dynavax Technologies Corp.

$ 1.28
DVAX
0.06
Short Interest (Shares Short)
1,062,900
Days To Cover (Short Interest Ratio)
1.7
Short Percent of Float
6.36 %
Short Interest - Prior
752,800
Short % Increase / Decrease
41.19 %
Short Squeeze Ranking™
36
% From 52-Wk High ($ 3.35 )
-161.72 %
% From 52-Wk Low ($ 0.15 )
88.28 %
% From 200-Day MA ($ 1.52 )
-18.75 %
% From 50-Day MA ($ 1.66 )
-29.69 %
Price % Change (52-Week)
335.70 %
Shares Float
16,720,000
Total Shares Outstanding
41,279,270
% Owned by Insiders
26.87 %
% Owned by Institutions
14.80 %
Market Cap.

$ 52,837,466
Trading Volume - Today
386,046
Trading Volume - Average
608,400
Trading Volume - Today vs. Average
63.45 %
Earnings Per Share
0.07
PE Ratio
18.30
Record Date
2009-OctB
Sector
Healthcare
Industry
Drug Manufacturers - Other
Exchange
NAS
http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…" target="_blank" rel="nofollow ugc noopener">
http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

[Lucky72]

Mal schaun ob die Burgerboys heut noch in die Puschen kommen!

[Lucky72]

Bid: 1.29 x 900
Ask: 1.30 x 22000

[Lucky72]

Verdächtig Ruhig!!!

[Lucky72]

NEWS!!!!!

Dynavax to Acquire Symphony Dynamo, Inc., Including $20 Million in Unrestricted Cash
Proceeds Fund HEPLISAV Registration Trials

* Press Release
* Source: Dynavax Technologies
* On 6:45 am EST, Tuesday November 10, 2009

*
Companies:
o Dynavax Technologies Corporation

BERKELEY, CA--(Marketwire - 11/10/09) - Dynavax Technologies Corporation (NASDAQVAX - News) announced today that it has exercised its option to purchase all of the equity of Symphony Dynamo, Inc. (SDI). As a result, Dynavax will acquire approximately $20 million in cash and regain all rights to its hepatitis C and cancer therapy programs. The transaction, described below, is subject to Dynavax stockholder approval, and is expected to close in the first quarter of 2010.

"This transaction is an important milestone for Dynavax, providing approximately $20 million in cash to fund HEPLISAV�, which represents the majority of the funding needed for the Phase 3 registration trials for our investigational adult hepatitis B vaccine," commented Dino Dina, M.D., President and Chief Executive Officer of Dynavax. "Our Hepatitis C clinical program, funded through SDI, has demonstrated safety and reproducible antiviral activity in a Phase 1b trial. With Symphony, we have decided to seek partners for HCV and focus our resources on HEPLISAV."

Dynavax and Symphony Capital Partners, LP (Symphony) have negotiated new terms to satisfy the exercise price for Dynavax's option to acquire SDI. Under this agreement, Dynavax will:

�
-- Acquire the cash held by SDI, currently $20.446 million, and issue to
Symphony 13 million shares of Dynavax Common Stock, which represents $1.57
per share
-- Issue 5-year warrants to Symphony for 2 million shares of Dynavax
Common Stock at an exercise price of $1.94 per share and cancel Symphony's
currently outstanding warrants for 2 million shares
-- Reacquire the rights to Dynavax's proprietary technology for its
hepatitis C and cancer therapies. If Dynavax partners these programs,
Symphony will receive 50% of the first $50 million from any potential
upfront and development milestones received.
-- Defer the existing $15 million obligation due to Symphony by 20 months
(until December 31, 2012) and convert the obligation previously payable
solely in cash, to payable in stock and/or cash at Dynavax's election


Upon closing, Symphony and its co-investors are expected to own approximately 24% of total Dynavax Common Stock outstanding. Dynavax will also expand its Board of Directors to include one Director designated by Symphony and one independent Director acceptable to both Symphony and Dynavax, as long as Symphony's ownership exceeds more than 10% of the total Dynavax Common Stock outstanding.

"We are impressed with the progress Dynavax has made with its pipeline of products targeting infectious diseases and are excited about the market opportunity for HEPLISAV," said Harri V. Taranto, Co-Founder of Symphony Capital. "We are pleased that this transition will enable Dynavax to fund HEPLISAV to realize its value creation potential for Dynavax."

About Symphony Dynamo, Inc. (SDI)

SDI was capitalized with $50 million in April 2006 by Symphony Capital Partners, LP and its co-investors to advance certain of Dynavax's programs for hepatitis B, hepatitis C, and cancer therapies. In April 2007, Dynavax exercised its option to purchase the hepatitis B therapy program.

Wedbush PacGrow Life Sciences acted as advisor to Dynavax in this transaction.

Conference Call

Dynavax will webcast a conference call today at 9:00 a.m. ET (6:00 a.m. PT). The live and archived webcast can be accessed by visiting the investor relations section of the Company's Web site at http://investors.dynavax.com/newsevents.cfm.

About Symphony Capital, LP

Symphony Capital LLC is a private equity firm dedicated to collaborating with leading innovative biopharmaceutical companies, helping them capture more of the value in their most important clinical development programs. Symphony's unique investment strategy brings a combination of dedicated capital, deep industry expertise and tailored investment structures to biopharmaceutical companies with compelling pipelines of products in all stages of clinical development. Additional information about Symphony is available at www.symphonycapital.com.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward-Looking Statements

This press release contains "forward-looking statements," that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether stockholder approval can be obtained, whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development, whether the studies can support registration for commercialization of HEPLISAV, initiation and completion of clinical trials of the Company's other product candidates; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process; the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

RULE 14a-12 LEGEND

Participants in Solicitation

Dynavax Technologies Corporation and its directors and officers may be deemed to be participants in the solicitation of proxies from Dynavax stockholders in connection with the exercise of the option to acquire the Symphony Dynamo equity. Information about the directors and executive officers of Dynavax and their ownership of Dynavax's stock is set forth in the proxy statement for Dynavax's 2009 Annual Meeting of Stockholders.

Investors can obtain more information when the proxy statement relating to stockholder approval of the issuance of shares in connection with the exercise of the option becomes available. This proxy statement, and any other documents filed by Dynavax with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. Investors should read the proxy statement carefully, when it becomes available, before making any voting decision because it will contain important information.

http://finance.yahoo.com/news/Dynavax-to-Acquire-Symphony-iw…

[Lucky72]

Nov. 10, 2009, 6:59 a.m.
Dynavax to buy Symphony Dynamo
Related stories

DVAX

LONDON (MarketWatch) -- Biopharmaceutical firm Dynavax Technologies Corp.(DVAX 1.28, 0.00, 0.00%) on Tuesday said it had exercised its option to purchase all of the equity of Symphony Dynamo Inc. As a result, Berkeley, Calif.-based Dynavax will acquire approximately $20 million in cash and regain all rights to its hepatitis C and cancer therapy programs, the company said. The transaction is subject to approval by Dynavax shareholders and is expected to close in the first quarter of next year. When the deal closes, Symphony and its co-investors are expected to own around 24% of total outstanding Dynavax common stock



http://www.marketwatch.com/story/dynavax-to-buy-symphony-dyn…

[roofy]

hmm ne firma kaufen die einem irgendwie schon gehört??

[Lucky72]

[Lucky72]

Ich wollte eigentlich eine "Short Squeeze" sehn!

[Lucky72]

Langsam kommt Volumen!

[Lucky72]

Form 8-K for DYNAVAX TECHNOLOGIES CORP

10-Nov-2009

Entry into a Material Definitive Agreement, Financial Statements and Ex


Item 1.01. Entry into a Material Definitive Agreement

On April 18, 2006, Dynavax Technologies Corporation ("Dynavax") entered into a series of related agreements with Symphony Capital Partners, LP ("Symphony"), Symphony Dynamo Holdings LLC ("Holdings") and Symphony Dynamo, Inc. ("SDI"), pursuant to which Holdings formed and capitalized SDI. Dynavax granted an exclusive license to the intellectual property for certain ISS compounds for cancer, hepatitis B and hepatitis C therapies (the "Development Programs") to SDI in consideration for a commitment from Symphony to provide $50 million of capital to advance the Development Programs. As part of the arrangement, Dynavax received an exclusive purchase option (the "Purchase Option") to acquire all the Development Programs through the purchase of all of the equity in SDI at specified prices. In exchange for the Purchase Option, Dynavax granted Holdings five-year warrants to purchase 2,000,000 shares of Dynavax's common stock at an exercise price of $7.32 per share pursuant to a warrant purchase agreement, and granted certain registration rights to Holdings pursuant to a registration rights agreement. Dynavax also received an exclusive option to purchase either the hepatitis B or hepatitis C program (the "Program Option") during the first year of the arrangement. In April 2007, Dynavax exercised its Program Option for the hepatitis B program. The exercise of this Program Option triggered a payment obligation of $15 million which would be either (a) due to Symphony upon the expiration of the SDI collaboration in 2011 if the Purchase Option is not exercised; or (b) included as part of the applicable purchase price upon exercise of the Purchase Option.

On November 9, 2009, Dynavax and Holdings entered into a series of related agreements pursuant to which the parties agreed to amend the terms of the Purchase Option and Program Option, as set forth in an amended and restated purchase option agreement (the "Amended Purchase Option Agreement"). In connection with such amendments, Dynavax and Holdings also entered into a warrant purchase agreement (the "Warrant Purchase Agreement"), an amended and restated registration rights agreement (the "Amended Registration Rights Agreement"), and a promissory note (the "Note") with Holdings (such agreements, together with the Amended Purchase Option Agreement, are collectively referred to as the "Transaction Documents").

Concurrently with the execution of the Transaction Documents, Dynavax notified Holdings of its exercise of the Purchase Option, pursuant to the Amended Purchase Option Agreement.

The Amended Purchase Option Agreement provides that, upon the closing of the Purchase Option, Dynavax will:

(i) issue to Holdings 13,000,000 shares of its common stock (the "Shares") in exchange for the cash held by SDI of $20.4 million, which represents a share price of $1.57 per share;

(ii) issue to Holdings five-year warrants to purchase 2,000,000 shares of its common stock (the "Warrant"), at an exercise price of $1.94 per share, which represents a 25% premium over Dynavax's preceding 30 trading-day volume weighted-average price per share of $1.55 through November 9, 2009, pursuant to the Warrant Purchase Agreement. The warrants issued initially to Holdings on April 18, 2006 will be cancelled concurrently with the issuance of the Warrant. Dynavax has agreed to provide certain registration rights under the Securities Act of 1933, as amended, with respect to the Shares and the shares of Dynavax's common stock issuable upon exercise of the Warrant pursuant to the Amended Registration Rights Agreement;
(iii) reacquire the rights to Dynavax's proprietary technology for its hepatitis C and cancer therapies. Holdings will be entitled to receive payments from Dynavax equal to 50% of the first $50 million from any upfront, pre-commercialization milestone or similar payments received by Dynavax from any agreement with a third party with respect to the development and/or commercialization of Dynavax's hepatitis C and cancer therapies; and

(iv) enter into the Note with Holdings to defer the $15 million Program Option obligation due to Symphony by 20 months (until December 31, 2012) and convert the obligation previously payable solely in cash, to payable in stock and/or cash at Dynavax's election.

In connection with the closing of the Purchase Option, Dynavax will also expand its Board of Directors to include one director designated by Holdings and one independent director acceptable to both Holdings and Dynavax, as long as Holdings' ownership exceeds more than 10% of the total Dynavax common stock outstanding. Holdings also agreed to certain limitations on its ability acquire additional securities of Dynavax, vote its shares or take certain actions intended to influence control of Dynavax.

It is a condition to the effectiveness of the Transaction Documents and related closing of the Purchase Option that Dynavax receive the approval of its stockholders for the issuance of the Shares and the shares of Dynavax's common stock issuable upon exercise of the Warrants and payment of the Note. Dynavax has agreed to use commercially reasonable efforts to obtain such stockholder approval.

Except as described herein, the transaction agreements among Dynavax, Symphony Capital, Holdings and SDI entered into on April 18, 2006 remain unchanged and in full force and effect.

On November 10, 2009, Dynavax issued a press release describing the transactions described herein. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.



Item 9.01. Financial Statements and Exhibits

(d) Exhibit Exhibit No. Description
99.1 Press Release, dated November 10, 2009, titled "Dynavax to Acquire Symphony Dynamo, Inc., Including $20 Million in Unrestricted Cash."

http://biz.yahoo.com/e/091110/dvax8-k.html

[Lucky72]

Time & Sales
Price Size Exch Time

1.44 5701 NGS 16:00:02
1.40 400 NGS 15:59:56
1.42 113 NYE 15:59:55
1.42 300 NYE 15:59:55
1.43 100 ISE 15:59:54

[Lucky72]

Nur zur Info!
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DVAX#g…

[Lucky72]

Der Chart sieht gut aus!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

Morgen kanns weiter UP gehn!

[Lucky72]

After Hours Charts

http://www.nasdaq.com/aspxcontent/ExtendedTradingCharts.aspx…

[Lucky72]

Gute Nacht

[Lucky72]

Guten Morgen

[Lucky72]

After Hours: $ 1.48 0.04 (+2.78%) Volume: 3.7 k 18:20 EST 10.11.2009

Time & Sales
Price Size Exch Time
1.48 100 NDD 18:20:34
1.46 1000 NDD 18:20:03
1.45 800 NGS 18:19:25
1.44 100 NDD 18:19:24
1.40 200 NGS 16:49:36

[Lucky72]

Dynavax Technologies Corp.

$ 1.44
DVAX
0.16
Short Interest (Shares Short)
879,000
Days To Cover (Short Interest Ratio)
1.1
Short Percent of Float
5.11 %
Short Interest - Prior
1,062,900
Short % Increase / Decrease
-17.30 %
Short Squeeze Ranking™
24


http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

Kein Handel in D!

Warten wohl alle mit dem Kaufen bis der Kurs bei 2$ steht!

[Lucky72]

[Lucky72]

Gap close!!!!!

[Lucky72]

Jetzt können die Shorty in Ruhe covern!

[Lucky72]

Noch eine Stunde! Mein Tipp SK 1,45$

[Lucky72]

Wird wohl nix!

[Lucky72]

William Harris Investors Inc Institution 723,200 Sold Some -101,800

http://www.mffais.com/dvaX

[Lucky72]

Confirmation # 9041482

Page 1

DYNAVAX

Moderator: Michael Ostrach

November 10, 2009

8:00 am CT

Operator: Thank you for joining us for today’s Dynavax Conference Call. As a reminder, today’s call is being recorded.

Participating on today’s call are; Dr. Dino Dina, President and CEO; Michael Ostrach, Vice President and Chief Business Officer, and Jennifer Lew, Vice President of Finance.

I will now turn the call over to Mr. Michael Ostrach. Please go ahead, sir.

Michael Ostrach: Thank you, Elizabeth. Today, we announced an agreement to acquire Symphony Dynamo, including approximately $20 million in unrestricted cash to support HEPLISAV’s registration trials. A copy of our press release can be found on our Web site, at www.dynavax.com.

On today’s call, we need to advise that we will be using forward-looking statements that are subject to a number of risks and uncertainties including statements relating to the timing of stockholder approval of this transaction, the nature and timing of planned clinical trials of HEPLISAV and our other product candidates and the development in commercial plans and expectations for HEPLISAV.

DYNAVAX

Moderator: Michael Ostrach

11-10-09/8:00 am CT

Confirmation # 9041482

Page 2



Actual results may differ materially due to the risks and uncertainties inherent in our business, including whether this transaction will be approved by stockholders, whether successful clinical development and regulatory approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development, our ability to obtain additional financing to support commercialization and development of HEPLISAV and our other operations, possible claims against us based on the patent rights of others and other risks detailed in the Risk Factors section in our current SEC reports. Dynavax undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Specifically for today’s conference call, I would add that the transaction with Symphony Dynamo will require Dynavax stockholder approval, and Dynavax expects to submit a preliminary proxy statement with the SEC in the near future. Dynavax and its directors and officers may be deemed to be participants in the solicitation of proxies from Dynavax stockholders in connection with the exercise of the option to acquire the Symphony Dynamo equity.

Information about the directors and executive officers of Dynavax and their ownership of Dynavax as stock is set forth in our proxy statement for Dynavax’s 2009 annual meeting of stockholders, which can be obtained from the SEC. Investors can obtain more information when the proxy statement relating to stockholder approval of the issuance of shares and other consideration in connection with the exercise of the option becomes available. This proxy statement and any other documents filed by Dynavax with the SEC may be obtained free of charge at the SEC Web site, at www.sec.gov. Investors should read the proxy statement carefully when it becomes available before making any voting decision because it will contain important information.

Finally, and now I would like to turn the call over to our CEO, Dino.

DYNAVAX

Moderator: Michael Ostrach

11-10-09/8:00 am CT

Confirmation # 9041482

Page 3



Dr. Dino Dina: Thank you, Michael. Had I known that we had such an introduction, I’d have caught a few minutes more of sleep today.

So today’s announcement is a significant accomplishment for Dynavax, and it helps us achieve the important corporate objectives. First, we secured approximately $20 million in cash to fund HEPLISAV, which represents the majority of funding required for the remaining registration trials.

With the cash funding from this transaction, we can focus on the implementation of our commercial strategy for HEPLISAV, which includes selling directly to concentrated market segments and has a key partnering strategy to expand the reach for the enhanced hepatitis B vaccine.

Second, we regained the rights to our hepatitis C and cancer therapy programs. As we’ve mentioned in recent announcements, our hepatitis C therapy has completed successfully a Phase IB trial, and we have now terminated our obligation to spend the remaining $20 million under SDI agreement on hep C, and instead we intent to prioritize partnering to complete the development of this therapy.

Now let’s spend a minute reviewing the specific terms of the transaction. Together with Symphony Capital, we’ve negotiated new terms for our option to acquire Symphony Dynamo, and the agreement includes the following terms. We will acquire the remaining cash in SDI, which is approximately $20 million, and in return for that, we will issue to Symphony 13 million shares of our stock, which translates to a price of $1.57 per share.

Upon closing of the transaction, Symphony is expected to earn approximately 24% of our total shares outstanding. We will also issue new 5 year warrants to Symphony for 2 million shares of our stock at a ((inaudible)) price of $1.94 per share and cancel the preexisting Symphony warrants.

DYNAVAX

Moderator: Michael Ostrach

11-10-09/8:00 am CT

Confirmation # 9041482

Page 4



In addition, we will reacquire the rights to proprietary technology for hepatitis C and the cancer therapy programs. As I mentioned, hep C has shown very good safety in the Phase IB study, and we have seen also notable and reproducible viral load reductions in treating people that have chronic hepatitis C infections. With the trial reaching its completion and no further funding obligations, we have decided to stop spending on this program for the time being. Our key priority now is to seek a partnership to advance the further development of the program. If the partnering activities are successful, Symphony will receive 50% of the first $50 million. That is a maximum of $25 million out of potential upfront payments and development milestones.

Finally, we have agreed to defer the existing $15 million liability for the repurchase of the hepatitis B therapy program due to Symphony in 20 months until December 31, 2012, and convert the obligation, which was previously payable in cash to being payable in stock or cash at our discretion. We will expand our board of directors to include one director designated by Symphony and one independent director acceptable to both Symphony and Dynavax as long as Symphony ownership exceeds more than 10% of the total Dynavax common stock outstanding.

To recap where all of this started and the original agreement in April of 2006, Symphony Dynamo was capitalized with $50 million in cash to fund therapies for hepatitis B, hepatitis C and cancer. The hepatitis B therapy program was repurchased in 2007, and to date, we’ve successfully completed a Phase IA and B clinical trials for hepatitis C therapy, which demonstrated safety and reproducible retroviral activity. Under the SDI agreement, we reserved the remaining 20 million to conduct additional studies, which are no longer under – planned as the result of the current transaction. Importantly, both Symphony and Dynavax with benefit if we’re successful in our partnering efforts, and we’ll keep you informed of our progress.

Even more importantly, with this transaction we have secured the majority of funding needed for HEPLISAV’s registration trials. In two previous Phase III trials, HEPLISAV has already demonstrated immunogenicity by providing more rapid increased protection against hepatitis B

DYNAVAX

Moderator: Michael Ostrach

11-10-09/8:00 am CT

Confirmation # 9041482

Page 5



viral infection. To support licensure, we have planned two registration trials, and the majority of the costs will be funded under the transaction that we announce today. First trial in approximately 600 chronic kidney disease patients has already started enrolling, and the second trial is planned to start at the beginning of 2010. It would be conducted in adults over 40 years of age to demonstrate lot to lot consistency for our manufacturing process.

In addition to our (involvement) in the regulatory process, we have the commercialization strategy for HEPLISAV, which targets servable high margin segments to obtain maximum value for Dynavax and our stockholders. For concentrated market segments such as chronic kidney disease patients, we intend to approach the market directly. Our goal is to sell as much of our HEPLISAV capacity to this segment and to capture the highest possible price for the vaccine we can produce in our Düsseldorf facility.

We also intend to reach broader segments in the U.S. such as chronic liver disease and HIV segments, and for markets outside of the U.S., we are pursuing partnering agreements to broaden the reach of these programs while providing additional cash for our HEPLISAV program. The funding from today’s transaction will provide us with an important time window to explore appropriate partnering opportunities for HEPLISAV in broad market segments and internationally.

Just to remind you then of the rest of our pipeline, we are continuing the development of hepatitis B therapy in the Phase IB trial, which requires only a modest investment to reach data in the second half of next year. We also are continuing our activities for the universal flu vaccine program that is still in preclinical development. We’re actively exploring funding options, including grants and other forms of support, to move the state of the art approach to – for influenza prevention into the clinic next year.

DYNAVAX

Moderator: Michael Ostrach

11-10-09/8:00 am CT

Confirmation # 9041482

Page 6



Our remaining programs, which include asthma and interventions in autoimmune disease, are under partnership agreement. We provide a valuable portion of our current revenues and future potential milestones as achieved.

I’ll now turn the call over to the operator and take questions.

Operator: Thank you. The question-and-answer session will be conducted electronically. If you would like to ask a question, please do so by pressing the star key following by the digit 1 on your touchtone telephone. If you are using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. Again, that is star 1 for questions, and we’ll pause for a moment to allow everyone a chance to signal. Once again, ladies and gentlemen, that is star 1 for questions or comments at this time.

And it appears that we have no questions.

Dr. Dino Dina: I think that there is a definite a possibility that, as it happened last time, this is due to people’s inability to sign in and ask questions. And so I apologize for those of you that may have questions and have not been able to ask them. We are, of course, available to take those by phone if you want to call the company directly.

But let me complete then our report today by thanking you for your interest and reiterating that the transaction that we just completed with Symphony represents really an important accomplishment, and it helps us meet several corporate objectives.

By securing approximately $20 million in cash for HEPLISAV, we’ll be able to fund the majority of future development costs for registration trials that are ongoing and that, with these fundings secured, we can now approach partnering opportunities for HEPLISAV that can be negotiated under much better terms.

DYNAVAX

Moderator: Michael Ostrach

11-10-09/8:00 am CT

Confirmation # 9041482

Page 7



Regaining rights to hepatitis C and cancer therapies allow us to focus resources on HEPLISAV on one side and then to start pursuing serious partnering activities to try and continue the development of hepatitis C. We would like to call on our stockholders and invite them to vote their proxy quickly as we anticipate the closing of this transaction in the first quarter of 2010.

We look forward to providing you corporate and pipeline updates as we continue with the implementation of our plans, and again, let me invite you to call us directly with your questions.

Thank you.

Operator: Once again that does conclude today’s conference call and we thank you for your participation.


http://ih.advfn.com/p.php?pid=nmona&cb=1258025017&article=40…

[Lucky72]

[Lucky72]

Die 1 Mil € Frage!

Wer kauft die ganzen Aktien????

[Lucky72]

Sehn wir heute noch 1,40$?

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag!

[Lucky72]

Hätte gestern fast geklappt mit den 1,40$!

Nur schade das der Markt abgekackt ist!

[Lucky72]

Freitag der 13.!

Ich hab 8,5k Dynavax im Depot! Ob das wohl gut geht??

[Lucky72]

Dynavax Technologies to acquire Symphony Dynamo
Thu. November 12, 2009; Posted: 09:54 AM
Stocks RSS

Nov 12, 2009 (Datamonitor via COMTEX) -- DVAX | Quote | Chart | News | PowerRating -- Dynavax Technologies has exercised its option to purchase all of the equity of Symphony Dynamo, a biopharmaceutical company.

As a result, Dynavax will acquire approximately $20 million in cash and regain all rights to its hepatitis C and cancer therapy programs. The transaction is subject to Dynavax stockholder approval, and is expected to close in the first quarter of 2010.

Dynavax and Symphony Capital Partners (Symphony) have negotiated new terms to satisfy the exercise price for Dynavax's option to acquire Symphony Dynamo (SDI).

Under this agreement, Dynavax will: acquire the cash held by SDI, currently $20.446 million, and issue to Symphony 13 million shares of Dynavax common stock, which represents $1.57 per share.

Upon closing, Symphony and its co-investors are expected to own approximately 24% of total Dynavax common stock outstanding. Dynavax will also expand its board of directors to include one director designated by Symphony and one independent director acceptable to both Symphony and Dynavax, as long as Symphony's ownership exceeds more than 10% of the total Dynavax common stock outstanding.

Dino Dina, president and CEO of Dynavax, said: "This transaction is an important milestone for Dynavax, providing approximately $20 million in cash to fund Heplisav, which represents the majority of the funding needed for the Phase III registration trials for our investigational adult hepatitis B vaccine.

"Our hepatitis C virus (HCV) clinical program, funded through SDI, has demonstrated safety and reproducible antiviral activity in a Phase Ib trial. With Symphony, we have decided to seek partners for HCV and focus our resources on Heplisav."


http://www.tradingmarkets.com/.site/news/Stock%20News/264790…

[Lucky72]

Ich glaube die Amis haben das letzte SEC Filing nich gelesen!

[Lucky72]

[Lucky72]

[Lucky72]

Falsche Richtung!!!

[Lucky72]

Punktlandung!

[Lucky72]

Totenstille in den US Boards!

[Lucky72]

Bin schon gespannt wann Dynavax ausbricht!

[Lucky72]

Aus dem Yahoo!

If a buyout of $5/share
Will you be happy?

http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_D/m…

[Lucky72]

Hier ist der Chart!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Gute Nacht @all

[Lucky72]

WOOOW! Hier wird sich wieder eingedeckt!!!!!

http://www.mffais.com/dvaX

[Lucky72]

So wo samma?

[Lucky72]

Der ganze Markt im Plus, aber Dynavax....!!!

[Lucky72]

Aus dem Yahoo!

Re: If a buyout of $5/share 32 minutes ago
Plagiarized from Captain:

The VALUE of a stock is not the same thing as the SHARE PRICE. These two things are often quite separate and IMO DVAX is significantly undervalued at present. Here is my back of the napkin value analysis for DVAX:

Cash $50 Million
Heplisav: ESRD market, conservative $100 Million/year for at LEAST $50M profit per year. X PE muliplier of 10 for market value of $500Million discount this by a conservative 50% chances of clearing the final trials without any more Wegeners or safety issues. Current market value IMO at least $250 million.
Universal flu: ? could be a billion/year product. Still a long way out. Chances of success ?. Value right now? Not Zero. Lets say $20 Million. I'd actually be pissed if they sold this for less than $200Million in milestones plus 10-15% royaties. This will go up sharply after PI completed in less than a year.
Auto Immune preclinical portfolio. Glaxo thinks this may be worth upto $800M plus royaties. Value right now? I dont know, $40Million?
Astra Zenica Asthma drug Lets say $10Million

So 50 cash
250 Heplisav
20 Universal flu
40 autoimmune portfolio
10 asthma preclinical
lets add in 50M for the ISS technology patent portfolio Hep C product, HepB treatment product peanut allergy product, Tolamba, etc.(remember Coly sold for $164 million)
--------
$420 Million total/ 39 million shares outstanding

This stock has a breakup value of over $10/share. Show me where I'm wrong.

I have to think that DVAX is a buyout target for someone.
I wont predict where the share price is going. The last two days have shown me that wall street is on drugs.

GLTA
Capt

http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_D/t…

[Lucky72]

Guten Morgen

[Lucky72]

Die Amis verpennen alles!

Kann bitte jemand den Link zur "MFFAI" Seite ins Yahoo oder IHUB stellen?

Hier ist der Link! http://www.mffais.com/dvaX

DANKE

[Lucky72]

[Lucky72]

Dino, we need some news!!!!

[Lucky72]

Big Pullback for Top Swine Flu Small-Caps

The H1N1 vaccine sector slipped on Tuesday, with some of the less speculative names being hit the worst

Investors have opted for future technology in lieu of proven performers during today's session, sending some of the only market-ready small-cap swine flu players lower by -5% or more. Meanwhile, Vical (NASDAQ: VICL - News) and Dynavax (NASDAQ: DVAX - News), whose H1N1 vaccines have yet to be approved, are among the sector's only winners for the session.


http://finance.yahoo.com/news/Big-Pullback-for-Top-Swine-ind…

[Lucky72]

Bei den Amis sind heute nur Taschengeldzocker unterwegs!

Die schaffen es nicht die 1,33$ zu knacken!

[Lucky72]

Das wird heut nix!

[Lucky72]

[Lucky72]

Gute Nacht @all

[Lucky72]

News are in the pipe!

[Lucky72]

Auf der CNBC Seite gab es auch einen Update!

http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

Die Jungs im Yahoo merken garnix!!!

[Lucky72]

Na endlich kommt Volumen!

[Lucky72]

Guten Morgen

Kommen bald Ergebnisse über Phase 3 von HEPLISAV™????

[Lucky72]

In dachte Phase 3 läuft schon seit August bei uns in Deutschland oder habe ich da was falsch verstanden?

[Lucky72]

Dynavax Announces European Development Strategy for HEPLISAV Hepatitis B Vaccine
BERKELEY, Calif., Aug 12, 2009

Hier ist der Link!

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=402…

[Lucky72]

http://files.shareholder.com/downloads/DVAX/753965771x0x2898…

[Lucky72]

NEEEWWWWSSSSS!!!!




Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy

BERKELEY, CA, Nov 19, 2009 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase 1b clinical trial. The safety profile of patients in the first cohort met pre-specified criteria for dose escalation and the second cohort has been opened for enrollment. Dynavax expects to report top-line data from this trial in the second half of 2010. DV-601 is the first hepatitis B therapy to combine both the surface and core HBV antigens, and Dynavax has retained all commercial rights to this product.

About the Phase 1b Hepatitis B Therapy Trial

In this open-label, dose-escalating Phase 1b trial being conducted in Europe, up to 30 patients will receive 6 injections of DV-601 over a three month period. The primary endpoints of this trial are safety and tolerability of DV-601. The secondary endpoints are immunologic and virologic measures of efficacy.

About HBV

Over 350 million individuals worldwide are chronically infected with the hepatitis B virus (HBV), which can lead to cirrhosis of the liver and liver cancer. The current worldwide market for HBV therapeutics is estimated to be over $1 billion annually and available therapies have modest efficacy.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward Looking Statements

This press release contains "forward-looking statements," that are subject to a number of risks and uncertainties, including when clinical trial data for DV-601 may be available. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether planned clinical trials for DV-601 can be timely completed; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process; the Company's ability to obtain additional financing to support the development of DV-601 and its other operations; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=425…

[Lucky72]

[Lucky72]

Bid: 1.27 x 13900
Ask: 1.28 x 800

[Lucky72]

[Lucky72]

Die News auf Googlisch!

http://translate.google.de/translate?hl=de&sl=en&u=http://in…

[Lucky72]

Guten Morgen

[Lucky72]

Hilfe!!!!

Was bedeutet das???

http://ih.advfn.com/p.php?pid=nmona&cb=1258701261&article=40…

[Lucky72]

Antwort auf Beitrag Nr.: 38.423.790 von Lucky72 am 20.11.09 08:17:40

OK! Wenn keiner eine meinung dazu hat werte ich es mal positiv!

[Lucky72]

Wenn der Markt dreht sind die Shorty angep...!

[Lucky72]

Dynavax completes enrollment for first cohort in Phase Ib hepatitis trial
Fri. November 20, 2009; Posted: 09:49 AM

Dynavax Technologies, a biopharmaceutical company, has completed enrollment for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase Ib clinical trial.

The safety profile of patients in the first cohort met pre-specified criteria for dose escalation and the second cohort has been opened for enrollment.

Dynavax expects to report topline data from this trial in the second half of 2010. DV-601 is reportedly the first hepatitis B virus (HBV) therapy to combine both the surface and core HBV antigens, and Dynavax has retained all commercial rights to this product.

In this open-label, dose-escalating Phase Ib trial being conducted in Europe, up to 30 patients will receive six injections of DV-601 over a three month period. The primary endpoints of this trial are safety and tolerability of DV-601. The secondary endpoints are immunologic and virologic measures of efficacy.

[Lucky72]

Bid: 1.25 x 12200
Ask: 1.26 x 1000

[Lucky72]

[Lucky72]

[Lucky72]

Test, Test!

[Lucky72]

Aus dem Yahoo!

Re: How Will you vote? 21-Nov-09 11:15 pm

What is strange is that they are increasing the total authorized shares from 100million to 150 million. Even with the new Symphony shares, the total outstanding shares + warrants + options would still only be 65 million shares. Wonder if they are contemplating a merger with another cash rich/product poor bio or perhaps trying to get a big pharma to make a big equity investment in DVAX instead of a buyout. I would probably prefer the latter as it brings eyeballs and credibility to the company almost instantly. In fact, the possible scenarios ranked in my order of preference would be:
1. Buyout of Dynavax at > $4 per share.
2. Partnership deal with big pharma/Equity investment by big pharma.
3. Big government grant for universal flu
4. Merger with cash rich bio.
5. Large private placement/shelf offering.

http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_D/t…

[Lucky72]

Nur zur Info!

http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DVAX#g…

[Lucky72]

Ich bin schon gespannt wann GSK ein Angebot macht!

[Lucky72]

Die "großen Jungs" haben sich jedenfalls schon mit Aktien eingedeckt!

[Lucky72]

Antwort auf Beitrag Nr.: 38.434.388 von Lucky72 am 22.11.09 20:30:59

http://www.mffais.com/dvax

[Lucky72]

Hier sind meiner Meinung nach viele Shorty am Werk!

Darum kommt der Kurs auch nicht in die Puschen!

[Lucky72]

Die Shorty hatten auch Erfolg!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Schön langsam wirds eng!

Ich habe einen EK von 1,22$ und wollte eigentlich nicht ins Minus rutschen!

[Lucky72]

Antwort auf Beitrag Nr.: 38.434.537 von Lucky72 am 22.11.09 21:26:32

Ach was solls dann leg ich nochmal nach!

[Lucky72]

Gute Nacht!

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag!

[Lucky72]

Heute Abend will ich die 1,40$ sehn!

[Lucky72]

[Lucky72]

Wo bleiben meine 1,40$?

[Lucky72]

Wird schon!

[Lucky72]

Support is broken!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Nur zur Info!


Biosciences, - Genocea Biosciences Expands Scientific Advisory Board with Appointment of Four Vaccine Experts
23.11.09 | 14:11 Uhr

Genocea Biosciences, a vaccine discovery and development company, today announced the appointments of David Bernstein, M.D., M.A., of the Cincinnati Children?s Hospital; Robert Coffman, Ph.D., of Dynavax Technologies; Patrice Dubois, Ph.D., of the University of Lausanne and Peter Kiener, D.Phil., of Zyngenia to its Scientific Advisory Board.The appointments of Drs.

Genocea Biosciences, a vaccine discovery and development company, today announced the appointments of David Bernstein, M.D., M.A., of the Cincinnati Children?s Hospital; Robert Coffman, Ph.D., of Dynavax Technologies; Patrice Dubois, Ph.D., of the University of Lausanne and Peter Kiener, D.Phil., of Zyngenia to its Scientific Advisory Board.

The appointments of Drs. Bernstein, Coffman, Dubois and Kiener further strengthen Genocea?s Scientific Advisory Board and their backgrounds complement those of the seven notable researchers from industry and academia who currently serve on the Board which includes George Siber,. M.D., Robert Finberg, M.D., Darren Higgins, Ph.D., David Sinclair, Ph.D., Penny Hitchcock, D.V.M., Richard Malley, M.D., and Adel Mahmoud, M.D., Ph.D. Genocea?s Scientific Advisory Board plays a critical role for the Company by providing scientific and industry guidance as the Company progresses its transformational vaccine platform to develop and commercialize vaccines for areas of high unmet medical need.

?It is an honor to add these distinguished scientists to our Advisory Board,? said Staph Leavenworth Bakali, President and Chief Executive Officer of Genocea. ?Each is a pioneer in the field of vaccine research and development, and we are fortunate to benefit from their collective counsel, critical knowledge and key scientific insights as we collaborate to advance Genocea?s innovative platform for vaccine discovery and development.?

New Scientific Advisory Board Members

David Bernstein, M.D., M.A.

Dr. Bernstein is the Albert Sabin Professor of Pediatrics and director of the Division of Infectious Diseases at Cincinnati Children?s Hospital, where he directs one of eight National Institutes of Health-funded Vaccine Evaluation Units. Dr. Bernstein has expertise in vaccines and antivirals against herpes simplex virus and cytomegalovirus, and was instrumental in the development of the precursor to the rotavirus vaccine, Rotarix®.

Robert Coffman, Ph.D.

Dr. Coffman is currently the vice president and chief scientific officer of Dynavax Technologies. He shared the William S. Coley Award for Research in Immunology for the discovery of the Th1 and Th2 subsets of T lymphocytes and is a member of the National Academy of Sciences. Prior to joining Dynavax, Dr. Coffman was a distinguished research fellow at the DNAX Research Institute.

Patrice Dubois, Ph.D.

Dr. Dubois is currently a freelance consultant in vaccine research and development. He was previously with Smith Kline Beecham (now GlaxoSmithKline), where he worked on the mode of action of adjuvants to evaluate vaccine-induced T cell responses. Dr. Dubois will begin work with the Global Adjuvant Development Initiative at the University of Lausanne in late 2009.

Peter Kiener, D.Phil.

Dr. Kiener is president and chief executive officer of Zyngenia, where he leads business and drug development efforts. Prior to founding Zyngenia, Dr. Kiener was head of research and development at MedImmune; before joining MedImmune, he held senior level research positions at Bristol-Myers Squibb. Dr. Kiener?s academic career includes positions on the Dean?s Advisory Board at the University of Maryland; assistant professor at the University of North Texas/Texas College of Osteopathic Medicine; research associate in the Department of Biochemistry, University of Massachusetts; and postdoctoral research assistant at the Sir William Dunn School of Pathology, Oxford University.

About Genocea Biosciences

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The company?s proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for Chlamydia trachomatis (a sexually transmitted disease agent causing an estimated 90 million cases worldwide), Streptococcus pneumoniae (pneumonia is the leading killer of children under the age of five worldwide) and other undisclosed targets. Genocea was recognized by BusinessWeek as one of the ?World?s Most Intriguing Startups? for 2009. In 2008, Genocea was selected as ?Best Vaccine Startup? at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, SR One, Auriga Partners, Cycad Group, Morningside Ventures and Alexandria Real Estate Equities. Visit www.genocea.com for more information.

http://www.ad-hoc-news.de/biosciences-genocea-biosciences-ex…

[Lucky72]

Langweilig!!!!

[Elmshorner]

Antwort auf Beitrag Nr.: 38.448.011 von Lucky72 am 24.11.09 20:00:24

Ja, es ist eine Schlaftablette

[Lucky72]

Antwort auf Beitrag Nr.: 38.448.079 von Elmshorner am 24.11.09 20:07:18

Lausiges Volumen und in den US Boards ist auch nix los!

[Lucky72]

Heute war Sequenom dran und morgen Dynavax!?

[Lucky72]

Heute war Sequenom dran und morgen Dynavax!??

[Lucky72]

Test!

[Lucky72]

Dynavax Technologies Corporation

Short Interest (Shares Short)
864,800
Days To Cover (Short Interest Ratio)
1.9
Short Percent of Float
2.41 %
Short Interest - Prior
879,000
Short % Increase / Decrease
-1.62 %
Short Squeeze Ranking™
33


http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

[Lucky72]

Guten Morgen

[Lucky72]

Alle Zeichen stehn auf "Grün"!

Dann kanns ja heute wieder UUUUPPPPP gehn!

[Lucky72]

Was geht ab?

[Lucky72]

Was für eine langweilige Aktie!

Hat Dynavax eine Nachrichtensperre??????

[Lucky72]

Der Kursverlauf stinkt zum Himmel!!!!

[Lucky72]

Gleich kackt sie wieder ab!

[Lucky72]

Antwort auf Beitrag Nr.: 38.498.297 von Lucky72 am 02.12.09 21:55:55

[Lucky72]

Heute kommen News!

[Lucky72]

Dino, wo bleibt meine News???

[Lucky72]

News!

http://investors.dynavax.com/secfiling.cfm?filingID=1193125-…

[Lucky72]

Noch eine News!

DYNAVAX TECHNOLOGIES CORPORATION

2929 Seventh Street, Suite 100

Berkeley, California 94710

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

To Be Held On December 30, 2009

Dear Stockholder:

Notice is hereby given that a Special Meeting of Stockholders of Dynavax Technologies Corporation, a Delaware corporation (the “Company”), will be held on the December 30, 2009 at 10:00 a.m. local time at the Company’s executive offices at 2929 Seventh Street, Suite 100, Berkeley, California 94710. In order to complete the acquisition of Symphony Dynamo, Inc. through which the Company will obtain approximately $20 million in cash and exclusive intellectual property rights, the Company is conducting this Special Meeting for the following purposes:


1. To approve the following issuances of shares of our Common Stock to Symphony Dynamo Holdings LLC (“Holdings”):

(a) 13,000,000 shares issuable pursuant to an Amended and Restated Purchase Option Agreement (the “Amended Purchase Option Agreement”), dated as of November 9, 2009, by and between the Company, Holdings and Symphony Dynamo, Inc. (“Dynamo”), as described in the attached proxy statement;

(b) 2,000,000 shares issuable upon exercise of warrants to be issued to Holdings pursuant to a Warrant Purchase Agreement, dated as of November 9, 2009, by and between the Company and Holdings, as described in the attached proxy statement; and

(c) up to $15 million worth of Common Stock issuable if we elect to pay Holdings in shares on the maturity date of a Promissory Note due December 31, 2012 pursuant to the Amended Purchase Option Agreement, as described in the attached proxy statement.


2. To approve an amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares.

These items of business are more fully described in the Proxy Statement accompanying this Notice.

The record date for the Special Meeting is November 18, 2009. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment or postponement thereof. In accordance with Delaware law, for ten days prior to the Special Meeting, a list of stockholders of record will be available for inspection in the office of the Corporate Secretary, Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710. The list of stockholders will also be available at the Special Meeting.

http://investors.dynavax.com/secfiling.cfm?filingID=1193125-…

[Lucky72]

[Lucky72]

Bid: 1.32 x 46400
Ask: 1.33 x 5100

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag und hoffe das Dynavax bald ausbricht!

[Lucky72]

NEEWWWSS!!!!!

Dynavax's European Manufacturing Facility Approved for Commercial Production of HEPLISAV Hepatitis B Surface Antigen

BERKELEY, CA and DUSSELDORF, GERMANY -- (Marketwire) -- 12/09/09 --

Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that its GMP manufacturing facility in Düsseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV™, the Company's investigational adult hepatitis B vaccine. The approval comes as a result of an upgrade expanding production capacity. With an updated European Union GMP manufacturing license in place, Dynavax can meet the initial commercial production demands for the anticipated launch of HEPLISAV

Dynavax's German subsidiary Rhein Biotech has manufactured the hepatitis B surface antigen for HEPLISAV clinical trials in this facility since 2006

The facility upgrade also enhances integrated product development and manufacturing services Rhein Biotech provides to third party partners

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine. In a completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response

About Hepatitis B Vaccines

Currently available hepatitis B vaccines require three doses over six months to achieve full immunogenicity in healthy patient populations

Because compliance with this vaccine regimen is low, new vaccines are needed to provide increased protection in a shorter timeframe. Furthermore, currently available vaccines do not fully address the needs of several patient populations, including those with chronic kidney disease, HIV or chronic liver disease. In particular, patients with comprised immune systems require both rapid and enhanced protection, either because they are less responsive to conventional vaccine regimens or because they are at high risk of infection

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com

About Dynavax Europe (Rhein Biotech GmbH)

Headquartered in Düsseldorf, Germany Dynavax's fully-owned subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market

For more information visit www.rheinbiotech.de

Forward Looking Statements

This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development, whether the studies can support registration for commercialization of HEPLISAV, the potential size and value of the chronic kidney disease market addressable with HEPLISAV, the commercial potential for HEPLISAV, and the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available

Contact: Michael Ostrach Vice President and Chief Business Officer 510-665-7257 Email Contact

http://ih.advfn.com/p.php?pid=nmona&cb=1260364348&article=40…

[Lucky72]

Es geht UUUUUPPPPPP!!!!!!

http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[Lucky72]

Bin raus!

Dankeschön!

[franzisca]

Die Fertigungsanlage in Europa von Dynavax erhält Zulassung für die kommerzielle Produktion des Hepatitis-B-Oberflächenantigens für HEPLISAV

© Marketwire 2009

(PR-inside.com 09.12.2009 17:12:36)
Drucken Ausdrucken
Artikel weiter empfehlen Per e-Mail empfehlen




BERKELEY, KALIFORNIERN und DÜSSELDORF, DEUTSCHLAND -- (Marketwire) -- 12/09/09 -- Dynavax Technologies Corporation (NASDAQ: DVAX) gab heute bekannt, dass die GMP-Fertigungsanlage in Düsseldorf (Deutschland) die Zulassung für die kommerzielle Produktion des Hepatitis-B-Oberflächenantigens, einer Kernkomponente von HEPLISAV™, dem Impfstoffkandidaten des Unternehmens gegen Hepatitis B bei Erwachsenen, erhalten hat. Diese Zulassung erfolgt infolge eines Ausbaus der Produktionskapazität. Jetzt, wo die aktualisierte GMP-Fertigungslizenz der Europäischen Union erteilt wurde, wird Dynavax den ersten kommerziellen Produktionsnachfragen für die lang erwartete Markteinführung von HEPLISAV gerecht werden können.



Rhein Biotech, das deutsche Tochterunternehmen von Dynavax, stellt das Hepatitis-B-Oberflächenantigen für die klinischen Studien mit HEPLISAV in dieser Anlage bereits seit 2006 her. Die Erweiterung der Anlage betrifft auch die Erweiterung der integrierten Produktentwicklungs- und Fertigungsdienstleistungen, die Rhein Biotech Dritten anbietet.



Informationen zu HEPLISAV


HEPLISAV ist ein Impfstoffkandidat gegen Hepatitis B für Erwachsene. In einer bereits abgeschlossenen, entscheidenden Studie der Phase 3 hat HEPLISAV einen verstärkten und schnell einsetzenden Schutz bei einer geringeren Dosierung als bei den derzeit zugelassenen Impfstoffen zeigen können. Dynavax hält die weltweiten Vermarktungsrechte an HEPLISAV und entwickelt den Impfstoff für große, hochwertige Populationen, die auf die derzeit zugelassenen Impfstoffe schlechter ansprechen, u. a. Personen mit chronischen Nierenleiden. HEPLISAV kombiniert ein Hepatitis-B-Oberflächenantigen mit einem firmeneigenen, unter der Bezeichnung ISS bekannten Toll-like-Rezeptor-9-Antagonisten, um die Immunreaktion zu verstärken.



Informationen zu Hepatitis-B-Impfstoffen


Derzeit verfügbaren Hepatitis-B-Impfstoffe erfordern drei Impfungen innerhalb von sechs Monaten, um bei gesunden Patienten eine vollständige Immunisierung zu erreichen. Aufgrund der geringen Compliance bei diesem Impfverfahren, sind neue Impfstoffe notwendig, um einen besseren Schutz in einem kürzeren Zeitraum zu erreichen. Darüber hinaus entsprechen derzeit verfügbare Impfstoffe nicht den Anforderungen mehrerer Patientenpopulationen, u. a. Patienten mit chronischen Nierenleiden, HIV-Infektionen bzw. chronischen Lebererkrankungen. Insbesondere Patienten mit beeinträchtigtem Immunsystem benötigen einen schneller einsetzenden und verstärkten Schutz, da sie entweder auf die herkömmlichen Impfstoffe weniger gut ansprechen oder weil sie einem höheren Infektionsrisiko unterliegen.



Informationen zu Dynavax


Dynavax Technologies Corporation, ein auf die klinische Phase spezialisiertes biopharmazeutisches Unternehmen, entdeckt und entwickelt neuartige Wirkstoffe zur Prävention und Behandlung von Infektionskrankheiten. HEPLISAV, der führende Wirkstoffkandidat des Unternehmens, ist ein in der Phase 3 befindlicher Impfstoffkandidat gegen Hepatitis B bei Erwachsenen, der darauf ausgerichtet ist, einen schneller einsetzenden und verstärkten Schutz bei einer geringeren Dosierung als bei derzeit zugelassenen Impfstoffen zu gewährleisten. Für weitergehende Informationen besuchen Sie bitte die Website unter www.dynavax.com.



Informationen zu Dynavax Europe (Rhein Biotech GmbH)


Die in Düsseldorf (Deutschland) ansässige Rhein Biotech, eine hundertprozentige Tochtergesellschaft von Dynavax, stellt das Hepatitis-B-Oberflächenantigen für HEPLISAV her. Rhein Biotech besteht seit 20 Jahren und bietet des Weiteren integrierte Produktentwicklungsdienstleistungen, die Partnerunternehmen bei der Markteinführung von Produkten unterstützen. Weitergehende Informationen stehen auf der Website unter www.rheinbiotech.de zur Verfügung.



Vorausschauende Aussagen


Die vorliegende Pressemitteilung enthält „vorausschauende Aussagen“, die einer Reihe von Risiken und Unwägbarkeiten unterliegen. Die tatsächlich eintretenden Ergebnisse können aufgrund der Risiken und Unwägbarkeiten, die mit unserer Geschäftstätigkeit einhergehen, wesentlich von den in der vorliegenden Pressemitteilung angegebenen abweichen. Zu diesen Risiken und Unwägbarkeiten gehören u. a.: - Die Frage, ob die klinische und aufsichtsrechtliche Entwicklung und Zulassung von HEPLISAV zeitgerecht und ohne wesentliche weitere Untersuchungen bzw. ohne Entwicklungsschwierigkeiten oder -verzögerungen erfolgreich abgeschlossen werden kann - Die Frage, ob die Studien für die kommerzielle Zulassung von HEPLISAV ausreichend sind - Die potentielle Größe und der Wert des mit HEPLISAV zu bedienenden Marktes chronischer Nierenleiden - Das kommerzielle Potenzial von HEPLISAV und die Möglichkeit, zusätzliche Finanzmittel zur Unterstützung der Entwicklung und Vermarktung von HEPLISAV und der anderen Tätigkeiten des Unternehmens zu erhalten - Mögliche Klagen gegen das Unternehmen aufgrund von Patentrechten Dritter sowie die Risiken, die im einzelnen im Abschnitt „Risk Factors“ der bei der SEC eingereichten Periodenberichte erörtert werden. Wir übernehmen keinerlei Verpflichtung, hier wiedergegebene Informationen aufgrund künftiger Ereignisse oder Umstände zu überarbeiten bzw. zu aktualisieren, selbst wenn neue Informationen verfügbar sind.



Ansprechpartner:
Michael Ostrach
Vice President und Chief Business Officer
Tel.: [phone]
E-Mail: [e-mail] :

[Lucky72]

Komm zu Papa!

Es gibt bald wieder Kaufkurse!

[LaPlue]

Special Shareholder Meeting am 30. Dezember....

viell. PartnershipNewS?

BUy

[Lucky72]

Ist der MM besoffen?

Realtime-Taxe für Dynavax Tech
WKN: 934210 ISIN: US2681581029
Geld: 1,07 Vol.: 5000
Brief: 1,00 Vol.: 5000
Zeit: 16:14:12 Datum: 21.12.2009

http://www.finanzen.net/realtime_stuttgart/Dynavax_Technolog…

[Lucky72]

[Lucky72]

Ist was im Busch!!

[Lucky72]

Bin wieder drin!

Jetzt kanns wieder UP gehn!

[Lucky72]

Komm schon Dino, raus mit der News!

[Lucky72]

Was geht eigentlich ab wenn sich die MA(50) und die MA(200) treffen?

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Der Kurs nimmt wohl erst Anlauf!

[Lucky72]

Guten Morgen

Die letzte News ist zwei Wochen her!

Ich denke das vor Weihnachten noch was kommt!

Ich wünsche uns eine dunkelgrünen Tag!

[Lucky72]

[Lucky72]

Was geht jetzt ab????

[Lucky72]

Nicht vergessen!!!

DYNAVAX TECHNOLOGIES CORPORATION

2929 Seventh Street, Suite 100

Berkeley, California 94710

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

To Be Held On December 30, 2009

Dear Stockholder:

Notice is hereby given that a Special Meeting of Stockholders of Dynavax Technologies Corporation, a Delaware corporation (the “Company”), will be held on the December 30, 2009 at 10:00 a.m. local time at the Company’s executive offices at 2929 Seventh Street, Suite 100, Berkeley, California 94710. In order to complete the acquisition of Symphony Dynamo, Inc. through which the Company will obtain approximately $20 million in cash and exclusive intellectual property rights, the Company is conducting this Special Meeting for the following purposes:


1. To approve the following issuances of shares of our Common Stock to Symphony Dynamo Holdings LLC (“Holdings”):

(a) 13,000,000 shares issuable pursuant to an Amended and Restated Purchase Option Agreement (the “Amended Purchase Option Agreement”), dated as of November 9, 2009, by and between the Company, Holdings and Symphony Dynamo, Inc. (“Dynamo”), as described in the attached proxy statement;

(b) 2,000,000 shares issuable upon exercise of warrants to be issued to Holdings pursuant to a Warrant Purchase Agreement, dated as of November 9, 2009, by and between the Company and Holdings, as described in the attached proxy statement; and

(c) up to $15 million worth of Common Stock issuable if we elect to pay Holdings in shares on the maturity date of a Promissory Note due December 31, 2012 pursuant to the Amended Purchase Option Agreement, as described in the attached proxy statement.


2. To approve an amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares.

These items of business are more fully described in the Proxy Statement accompanying this Notice.

The record date for the Special Meeting is November 18, 2009. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment or postponement thereof. In accordance with Delaware law, for ten days prior to the Special Meeting, a list of stockholders of record will be available for inspection in the office of the Corporate Secretary, Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710. The list of stockholders will also be available at the Special Meeting.

http://investors.dynavax.com/secfiling.cfm?filingID=1193125-…

[Lucky72]

Nächste Woche knallts!

MA (50) 1,40$
MA (200) 1,39$

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Nur zur Info!

Ich hoffe bei Dynavax gehts genau so schnell!

http://ih.advfn.com/p.php?pid=nmona&cb=1261815668&article=40…

[Lucky72]

Nicht vergessen!!!

Wirtschaft & Industrie

Die Fertigungsanlage in Europa von Dynavax erhält Zulassung für die kommerzielle Produktion des Hepatitis-B-Oberflächenantigens für HEPLISAV


© Marketwire 2009
09.12.2009 17:09:04 -

(live-PR.com) -

BERKELEY, KALIFORNIERN und DÜSSELDORF, DEUTSCHLAND -- (Marketwire) -- 12/09/09 --
Dynavax Technologies Corporation (NASDAQ: DVAX) gab heute bekannt, dass die GMP-Fertigungsanlage in Düsseldorf (Deutschland) die Zulassung für die kommerzielle Produktion des Hepatitis-B-Oberflächenantigens, einer Kernkomponente von HEPLISAV™, dem Impfstoffkandidaten des Unternehmens gegen Hepatitis B bei Erwachsenen, erhalten hat. Diese Zulassung erfolgt infolge eines Ausbaus der Produktionskapazität. Jetzt, wo die aktualisierte GMP-Fertigungslizenz der Europäischen Union erteilt wurde, wird Dynavax den ersten kommerziellen Produktionsnachfragen für die lang erwartete Markteinführung von HEPLISAV gerecht werden können.

Rhein Biotech, das deutsche Tochterunternehmen von Dynavax, stellt das Hepatitis-B-Oberflächenantigen für die klinischen Studien mit HEPLISAV in dieser Anlage bereits seit 2006 her. Die Erweiterung der Anlage betrifft auch die Erweiterung der integrierten Produktentwicklungs- und Fertigungsdienstleistungen, die Rhein Biotech Dritten anbietet.

Informationen zu HEPLISAV

HEPLISAV ist ein Impfstoffkandidat gegen Hepatitis B für Erwachsene. In einer bereits abgeschlossenen, entscheidenden Studie der Phase 3 hat HEPLISAV einen verstärkten und schnell einsetzenden Schutz bei einer geringeren Dosierung als bei den derzeit zugelassenen Impfstoffen zeigen können. Dynavax hält die weltweiten Vermarktungsrechte an HEPLISAV und entwickelt den Impfstoff für große, hochwertige Populationen, die auf die derzeit zugelassenen Impfstoffe schlechter ansprechen, u. a. Personen mit chronischen Nierenleiden. HEPLISAV kombiniert ein Hepatitis-B-Oberflächenantigen mit einem firmeneigenen, unter der Bezeichnung ISS bekannten Toll-like-Rezeptor-9-Antagonisten, um die Immunreaktion zu verstärken.

Informationen zu Hepatitis-B-Impfstoffen

Derzeit verfügbaren Hepatitis-B-Impfstoffe erfordern drei Impfungen innerhalb von sechs Monaten, um bei gesunden Patienten eine vollständige Immunisierung zu erreichen. Aufgrund der geringen Compliance bei diesem Impfverfahren, sind neue Impfstoffe notwendig, um einen besseren Schutz in einem kürzeren Zeitraum zu erreichen. Darüber hinaus entsprechen derzeit verfügbare Impfstoffe nicht den Anforderungen mehrerer Patientenpopulationen, u. a. Patienten mit chronischen Nierenleiden, HIV-Infektionen bzw. chronischen Lebererkrankungen. Insbesondere Patienten mit beeinträchtigtem Immunsystem benötigen einen schneller einsetzenden und verstärkten Schutz, da sie entweder auf die herkömmlichen Impfstoffe weniger gut ansprechen oder weil sie einem höheren Infektionsrisiko unterliegen.

Informationen zu Dynavax

Dynavax Technologies Corporation, ein auf die klinische Phase spezialisiertes biopharmazeutisches Unternehmen, entdeckt und entwickelt neuartige Wirkstoffe zur Prävention und Behandlung von Infektionskrankheiten. HEPLISAV, der führende Wirkstoffkandidat des Unternehmens, ist ein in der Phase 3 befindlicher Impfstoffkandidat gegen Hepatitis B bei Erwachsenen, der darauf ausgerichtet ist, einen schneller einsetzenden und verstärkten Schutz bei einer geringeren Dosierung als bei derzeit zugelassenen Impfstoffen zu gewährleisten. Für weitergehende Informationen besuchen Sie bitte die Website unter www.dynavax.com.

Informationen zu Dynavax Europe (Rhein Biotech GmbH)

Die in Düsseldorf (Deutschland) ansässige Rhein Biotech, eine hundertprozentige Tochtergesellschaft von Dynavax, stellt das Hepatitis-B-Oberflächenantigen für HEPLISAV her. Rhein Biotech besteht seit 20 Jahren und bietet des Weiteren integrierte Produktentwicklungsdienstleistungen, die Partnerunternehmen bei der Markteinführung von Produkten unterstützen. Weitergehende Informationen stehen auf der Website unter www.rheinbiotech.de zur Verfügung.

Vorausschauende Aussagen

Die vorliegende Pressemitteilung enthält „vorausschauende Aussagen“, die einer Reihe von Risiken und Unwägbarkeiten unterliegen. Die tatsächlich eintretenden Ergebnisse können aufgrund der Risiken und Unwägbarkeiten, die mit unserer Geschäftstätigkeit einhergehen, wesentlich von den in der vorliegenden Pressemitteilung angegebenen abweichen. Zu diesen Risiken und Unwägbarkeiten gehören u. a.: - Die Frage, ob die klinische und aufsichtsrechtliche Entwicklung und Zulassung von HEPLISAV zeitgerecht und ohne wesentliche weitere Untersuchungen bzw. ohne Entwicklungsschwierigkeiten oder -verzögerungen erfolgreich abgeschlossen werden kann - Die Frage, ob die Studien für die kommerzielle Zulassung von HEPLISAV ausreichend sind - Die potentielle Größe und der Wert des mit HEPLISAV zu bedienenden Marktes chronischer Nierenleiden - Das kommerzielle Potenzial von HEPLISAV und die Möglichkeit, zusätzliche Finanzmittel zur Unterstützung der Entwicklung und Vermarktung von HEPLISAV und der anderen Tätigkeiten des Unternehmens zu erhalten - Mögliche Klagen gegen das Unternehmen aufgrund von Patentrechten Dritter sowie die Risiken, die im einzelnen im Abschnitt „Risk Factors“ der bei der SEC eingereichten Periodenberichte erörtert werden. Wir übernehmen keinerlei Verpflichtung, hier wiedergegebene Informationen aufgrund künftiger Ereignisse oder Umstände zu überarbeiten bzw. zu aktualisieren, selbst wenn neue Informationen verfügbar sind.

Ansprechpartner:
Michael Ostrach
Vice President und Chief Business Officer
Tel.: [phone]
E-Mail: [e-mail] : [e-mail]

http://www.live-pr.com/die-fertigungsanlage-in-europa-von-dy…

[Lucky72]

Nanu, keiner da!

[Lucky72]

Hier mal der Chart!

[Lucky72]

Sunday December 27, 2009 20 Min Delayed
Short Quote™
Enter Symbol:

Dynavax Technologies Corporation

$ 1.45
DVAX
0.01
Short Interest (Shares Short)
843,900
Days To Cover (Short Interest Ratio)
0.6
Short Percent of Float
2.35 %
Short Interest - Prior
848,200
Short % Increase / Decrease
-0.51 %
Short Squeeze Ranking™
1
% From 52-Wk High ($ 3.35 )
-131.03 %
% From 52-Wk Low ($ 0.50 )
65.52 %
% From 200-Day MA ($ 1.57 )
-8.28 %
% From 50-Day MA ($ 1.37 )
5.52 %
Price % Change (52-Week)
64.80 %
Shares Float
35,852,430
Total Shares Outstanding
41,279,270
% Owned by Insiders
10.20 %
% Owned by Institutions
27.10 %
Market Cap.

$ 59,854,942
Trading Volume - Today
162,594
Trading Volume - Average
1,322,100
Trading Volume - Today vs. Average
12.30 %
Earnings Per Share
0.07
PE Ratio
20.70
Record Date
2009-DecB
Sector
Healthcare
Industry
Drug Manufacturers - Other
Exchange
NAS


http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

Nur zur Info!

http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

Hier ist der Link zur HP!

http://www.dynavax.com/

[Lucky72]

Mal schaun ob hier Schwung in die Bude kommt!

[Lucky72]

Totenstille bei den Amis!

[Lucky72]

Boah, ist das Fad!

Das Warten kann einen richtig kirre machen!

[Lucky72]

Ich hätte eigentlich schon gehofft das was durchsickert!

[Lucky72]

Wednesday, December 9, 2009
Dynavax gets OK at German factory for hepatitis vaccine work

Dynavax Technologies Corp. got approval from European regulators to make part of its hepatitis B vaccine at a German factory.

The license from the European Union lets Berkeley-based Dynavax (NASDAQ: DVAX) make hepatitis B surface antigen for commercial use at the factory in Düsseldorf, in the west central part of Germany.

Rhein Biotech GmbH, a German unit of Dynavax, used the factory to make the same antigen — part of the company’s Heplisav vaccine — for clinical trials starting in 2006. Since then the factory has been upgraded.

Heplisav has finished a Phase III clinical trial . The company hopes to market the vaccine to people who don’t respond well to current vaccines — people with chronic kidney disease, for example.

Zbigniew Janowicz is CEO of Rhein Biotech and Dino Dina, M.D., is CEO of Dynavax.


http://sanfrancisco.bizjournals.com/sanfrancisco/stories/200…

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag!

[Lucky72]

Nur zur Info!

Merck prüft Akquisitionsmöglichkeiten

http://www.finanznachrichten.de/nachrichten-aktien/merck-kga…

[Lucky72]

Hier ist viel "Phantasie" drin!

[Lucky72]

[Lucky72]

Last Trade: 1.41
Trade Time: 1:57pm ET
Change: Down 0.04 (2.76%)
Prev Close: 1.45
Open: 1.42
Bid: 1.41 x 800
Ask: 1.42 x 25300

[Lucky72]

Guten Morgen

[Lucky72]

Keine News!

[Lucky72]

Bin schon gespannt wohin die Reise heute geht!

Morgen ist das "SPECIAL MEETING OF STOCKHOLDERS"!!!

[Lucky72]

[Lucky72]

Langsam kommt bewegung rein!

[Lucky72]

Kaum geh ich eine Stunde zum Schneeschaufeln und schon kackt der Kurs ab!

[Lucky72]

Last Trade: 1.44
Trade Time: 1:36pm ET
Change: Up 0.04 (2.86%)
Prev Close: 1.40
Open: 1.38
Bid: 1.44 x 74600
Ask: 1.45 x 10200

[Lucky72]

Es geht wieder los!

[Lucky72]

[Lucky72]

Der Chart!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Guten Morgen

After Hours: $ 1.50 0.01 (+0.67%) Volume: 400 19:06 EST 29.12.2009

[Lucky72]

Das muß ja ein geiles Meeting sein!

[Lucky72]

Die haben wohl Handyverbot!

[Lucky72]

Guten Morgen

Depth/Level II for Dynavax Technologies Corp. (DVAX)
$ 1.43 -0.06 (-4.03%) Volume: 236.28 k 15:59 EST 30.12.2009

After Hours: $ 1.46 0.03 (+2.10%) Volume: 4.52 k 17:12 EST 30.12.2009

[Lucky72]

Noch keine News!

[Lucky72]

[Lucky72]

[Lucky72]

Es gibt News!!!!!

Dynavax Completes Symphony Dynamo Acquisition
$20 Million Cash Proceeds to Support HEPLISAV Registration Trials

BERKELEY, CA, Jan 04, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that stockholders approved the acquisition of Symphony Dynamo, Inc. (SDI), including approximately $20 million in cash and all rights to Dynavax's hepatitis C and cancer therapy programs.

Dynavax expects the proceeds from this transaction to contribute significantly toward the completion of its registration trials for HEPLISAV(TM), the Company's investigational adult hepatitis B vaccine.

In November 2009, Dynavax and Symphony Capital Partners, LP (Symphony) announced new terms to satisfy the exercise price for Dynavax's option to acquire SDI. Under this agreement, Dynavax:

-- Acquired approximately $20 million in cash held by SDI, and issued to
Symphony 13 million shares of Dynavax Common Stock
-- Issued 5-year warrants to Symphony for 2 million shares of Dynavax Common
Stock at an exercise price of $1.94 per share and cancelled Symphony's
currently outstanding warrants for 2 million shares
-- Reacquired the rights to Dynavax's proprietary technology for its
hepatitis C and cancer therapies. If Dynavax partners these programs,
Symphony will receive 50% of the first $50 million from any potential
upfront and development milestones received.
-- Deferred a $15 million obligation due to Symphony by 20 months (until
December 31, 2012) and converted the obligation previously payable solely
in cash, to payable in stock and/or cash at Dynavax's election



Following this transaction, Symphony and its co-investors own approximately 24% of total Dynavax Common Stock outstanding. Dynavax has expanded its Board of Directors to include Mark Kessel, Partner, Symphony Capital LLC. As part of the agreement, one independent Director acceptable to both Symphony and Dynavax will be appointed, as long as Symphony's ownership exceeds more than 10% of the total Dynavax Common Stock outstanding.

Wedbush PacGrow Life Sciences acted as advisor to Dynavax in this transaction.

About Symphony Dynamo, Inc. (SDI)

SDI was capitalized with $50 million in April 2006 by Symphony Capital Partners, LP and its co-investors to advance certain of Dynavax's programs for hepatitis B, hepatitis C, and cancer therapies. In April 2007, Dynavax exercised its option to purchase the hepatitis B therapy program.

About Symphony Capital LLC

Symphony Capital LLC is a private equity firm dedicated to collaborating with leading innovative biopharmaceutical companies, helping them capture more of the value in their most important clinical development programs. Symphony's unique investment strategy brings a combination of dedicated capital, deep industry expertise and tailored investment structures to biopharmaceutical companies with compelling pipelines of products in all stages of clinical development. Additional information about Symphony is available at www.symphonycapital.com.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information, visit www.dynavax.com.

Forward-Looking Statements

This press release contains "forward-looking statements," that are subject to a number of risks and uncertainties, including the expected use of proceeds from the acquisition of Symphony Dynamo, Inc. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development, whether the studies can support registration for commercialization of HEPLISAV, initiation and completion of clinical trials of the Company's other product candidates; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process; the Company's ability to obtain additional financing to complete the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies Corporation

http://www2.marketwire.com/mw/emailprcntct?id=7A1943BA96D5EE…

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=433…

[Lucky72]

Form 8-K for DYNAVAX TECHNOLOGIES CORP

4-Jan-2010

Entry into a Material Definitive Agreement, Termination of a Material D


Item 1.01. Entry into a Material Definitive Agreement

On December 30, 2009, Dynavax Technologies Corporation ("Dynavax" or the "Company") completed the acquisition of all of the outstanding equity securities of Symphony Dynamo, Inc. ("SDI") from Symphony Dynamo Holdings LLC ("Holdings") pursuant to the option granted to Dynavax under the Amended and Restated Purchase Option Agreement, dated as of November 9, 2009, by and among the Company, Holdings and SDI. In connection with the closing of this transaction, the Company acquired approximately $20 million in cash held by SDI, reacquired the rights to its proprietary technology for hepatitis C and cancer therapies issued to Symphony Capital Partners, L.P. and certain co-investors (the "Symphony Dynamo Investors"):

(i) 13,000,000 shares of the Company's common stock (the "Shares"),
(ii) Warrants to purchase an aggregate of 2,000,000 shares of the Company's common stock (the "Warrants"), pursuant to a Warrant Purchase Agreement dated as of November 9, 2009, by and between the Company and Holdings, and
(iii) A Promissory Note ("Note") in the principal amount of $15 million due December 31, 2012, payable in cash, our common stock or a combination thereof.

Upon the closing of the transaction, SDI became a wholly owned subsidiary of the Company. In April 2006, the Company entered into a series of related agreements with Symphony Capital Partners, L.P. ("Symphony"), Holdings and SDI, pursuant to which Holdings formed and capitalized SDI to fund development of certain ISS compounds for cancer, hepatitis B and hepatitis C therapies (the "Development Programs") in exchange for a commitment from Symphony to provide $50 million of capital to advance the Development Programs. As part of the arrangement, Dynavax received an exclusive purchase option (the "Purchase Option") to acquire all the Development Programs through the purchase of all of the equity in SDI at specified prices. In April 2007, Dynavax exercised its Program Option for the hepatitis B program. The exercise of this Program Option triggered a payment obligation of $15 million which was either (a) due to Symphony upon the expiration of the SDI collaboration in 2011 if the Purchase Option was not exercised; or (b) included as part of the applicable purchase price upon exercise of the Purchase Option. The Company has historically consolidated the assets, liabilities and financial results of SDI into its financial statements since the grant of the purchase option at the inception of the arrangements with Symphony in April 2006 as described above.

Upon the issuance of the Warrants, the warrants initially issued to Holdings on April 28, 2006 for the purchase of 2,000,000 shares of the Company's common stock at an exercise price of $7.32 per share, which warrants otherwise had terms and conditions that were substantially similar to those of the Warrants, were cancelled. The Warrants issued upon closing of the transaction have an exercise price of $1.94 per share and a cashless exercise provision under which its holder may, in lieu of payment of the exercise price in cash, surrender such Warrants and receive a net amount of shares based on the fair market value of the Company's common stock at the time of exercise of such Warrants after deduction of the aggregate exercise price. The Warrants contain provisions for the adjustment of the exercise price and the number of shares issuable upon exercise in the event of certain stock dividends, stock splits, reorganizations and reclassifications. In the event of a merger or acquisition in which the surviving or resulting parent entity is an entity other than the Company, the Warrants also provide for the issuance of a replacement warrant that is exercisable for shares of the surviving entity or the surrender of such Warrants in consideration of a specified cash payment for each share of the Company's common stock subject to such Warrants, depending on the consideration paid by . . .


Item 1.02. Termination of a Material Definitive Agreement

The disclosure provided in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 1.02.



Item 2.01. Completion of Acquisition or Disposition of Assets

The disclosure provided in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 2.01.



Item 3.02. Unregistered Sales of Equity Securities

The disclosure provided in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 3.02. The Company believes that each of the Symphony Dynamo Investors are "accredited investors," and the issuance of the Shares and the Warrants was therefore made pursuant to Regulation D promulgated under the Securities Act of 1933, as amended.



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Effective on December 30, 2009, the Board of Directors (the "Board") of Dynavax elected Mark Kessel as a Class I director to serve until the 2010 Annual Meeting of Stockholders. In accordance with the Corporate Governance Agreement, dated as of December 30, 2009, between the Company and Holdings, the Company had agreed to nominate and use its commercially reasonable efforts to cause to be elected and cause to remain as a director on the Board one (1) individual designated by Holdings. Mr. Kessel is such director designee. Mr. Kessel is a partner of Symphony Capital LLC. Pursuant to the terms of an offer letter between Dynavax and Mr. Kessel and the compensation policies of Dynavax with respect to outside directors, Mr. Kessel received the following as of his date of election:

1. Pursuant to the Dynavax 2004 Non-Employee Directors' Option Plan (the "Directors' Plan"), Mr. Kessel was granted an initial non-qualified stock option to purchase 20,000 shares of Dynavax common stock, with an exercise price equal to the fair market value on the date of grant, vesting over four years in equal annual installments;

2. Pursuant to the Directors' Plan, Mr. Kessel will automatically receive a non-qualified option to purchase an additional 10,000 shares of Dynavax common stock at each annual meeting of Dynavax's stockholders (with respect to the first such grant, the option will be pro-rated such that the fraction of such 10,000 shares shall equal the fraction of the year that he serves until the 2010 annual meeting), with an exercise price equal to the fair market value on the date of grant, vesting on the first anniversary of the grant; and

3. Mr. Kessel will receive an annual retainer of $20,000, payable in equal quarterly installments in arrears, $2,000 for each Board meeting attended in person and $500 for each Board meeting attended by telephone.



Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On December 30, 2009, the stockholders of the Company approved an amendment to the Company's Sixth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company's Common Stock, par value $0.001 from 100,000,000 shares to 150,000,000 shares. The increase in authorized shares was effected pursuant to a Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (the "Certificate of Amendment"), filed with the Secretary of State of the State of Delaware on December 30, 2009. A copy of the Certificate of Amendment is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated into this Item 5.03 by reference.



Item 9.01. Financial Statements and Exhibits

(a) The Company has historically consolidated the assets, liabilities and financial results of SDI into its financial statements since April 2006.

(b) The disclosures provided in the Company's Schedule 14A filed on December 3, 2009 are hereby incorporated by reference into this Item 9.01(b).

(d) Exhibit
Exhibit No. Description
3.1 Certificate of Amendment to the Sixth Amended and Restated


Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on December 30, 2009.

99.1 Press Release, dated January 4, 2010, titled "Dynavax Completes Symphony Dynamo Acquisition."


http://biz.yahoo.com/e/100104/dvax8-k.html

[Lucky72]

Monday, January 4, 2010, 9:25am PST
Dynavax wraps up Symphony Dynamo deal

Dynavax Technologies Corp. finished buying Symphony Dynamo Inc. in a stock deal.

Berkeley-based Dynavax (NASDAQ: DVAX) issued 13 million shares of its stock for the purchase, but in return it picked up $20 million in cash and rights to its own hepatitis C and cancer treatments held by Symphony Dynamo.

Dynavax also paid Symphony with 5-year warrants for 2 million more shares of its stock, while canceling existing warrants for 2 million shares Symphony had.

The deal also lets Dynavax, led by Dino Dina, M.D., defer a $15 million debt it owes to Symphony. That payment is now put off until Dec. 31, 2012 and it can be paid in stock and cash instead of just in stock.

Symphony now owns about 24 percent of Dynavax stock.

Dynavax plans to spend the $20 million on its Heplisav vaccine for hepatitis B.



http://sanfrancisco.bizjournals.com/sanfrancisco/stories/201…

[Lucky72]

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=69650…

[Lucky72]

Die News schlägt ein wie eine Bombe!!!

[Lucky72]

[Lucky72]

[Lucky72]

Shares Float
35,852,430
Total Shares Outstanding
41,279,270
% Owned by Insiders
10.20 %
% Owned by Institutions
27.10 %
Symphony now owns about 24% of Dynavax stock

Da bleibt nicht viel über!!!

[Lucky72]

WOW!!!

Was geht den heute ab?

[Lucky72]

Heute noch 1,60$???

[Lucky72]

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Trade Detail
After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18:39 $ 1.65 2,127
18:39 $ 1.65 523
18:33 $ 1.64 200


http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag!

[Lucky72]

Mach schon Dino rauß mit der News!

Ich will heute 2$ sehn!

[Lucky72]

Pre-Market!

http://www.nasdaq.com/aspxcontent/ExtendedTradingCharts.aspx…

[Lucky72]

[Lucky72]

@Dino
Wo bleiben meine News?

[Lucky72]

Ohne News wird das heute nix!

[Lucky72]

http://investors.dynavax.com/secfiling.cfm?filingID=1288320-…

[Lucky72]

Guten Morgen


Bricht sie heute aus?

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Kann bitte jemand die Amis aufwecken?!

[Lucky72]

AAAHHH! Die Amis haben ausgeschlafen!

[Lucky72]

Liegt vielleicht daran!?

http://investors.dynavax.com/secfiling.cfm?filingID=1193125-…

[Lucky72]

http://investors.dynavax.com/secfiling.cfm?filingID=1193125-…

[Lucky72]

http://investors.dynavax.com/sec.cfm

[Lucky72]

Dynavax Expands Commercial and Clinical Leadership

BERKELEY, CA, Jan 12, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the addition of two new senior executives to direct key commercial and clinical activities prior to the launch of HEPLISAV(TM), an investigational adult hepatitis B vaccine.

Brant Biehn, after more than 20 years with Merck, joins as Chief Commercial Development Officer. Mr. Biehn will be responsible for the development and execution of Dynavax's commercial strategy, including market development, sales, and distribution channel partnerships.

William Heyward, M.D., M.P.H., a distinguished epidemiologist and specialist in the design and conduct of licensure-directed clinical trials, joins as Vice President, Clinical Research. Dr. Heyward will manage the Company's two registration trials for HEPLISAV, for which approximately 70 centers in North America and Europe will enroll 2600 subjects.

Brant Biehn

Mr. Biehn held increasingly senior sales and marketing positions during his tenure at Merck. Since 2005, he has had responsibility for many adult vaccine products, including Merck's Hepatitis A, Hepatitis B and pneumococcal vaccines. Most recently, he served as International Market Lead for ZOSTAVAX(R), a vaccine launched in the US in 2005 for the prevention of herpes zoster, or shingles as well as Merck's other adult vaccines. Prior to 2009, in his role as a global brand leader, he designed and managed marketing and sales programs, including distribution channels; targeted marketing to customer groups, payers, healthcare professionals, and consumers; and led country-specific marketing for ex-US markets. Over the past two years he worked with countries worldwide to supply pneumococcal polysaccharide vaccine to help prevent secondary bacterial infections that may result from pandemic flu infection. This program extended to both large public health programs as well as private health groups, with an emphasis on prevention of pandemic flu impacts. Earlier in his career Mr. Biehn created and led national sales organizations and directed multiple marketing efforts aimed at commercialization planning for new vaccine and human health products. Mr. Biehn earned a Bachelor of Science in Computer Science from the Memorial University of Newfoundland.

William Heyward, M.D., M.P.H.

Dr. Heyward brings to Dynavax an expertise in hepatitis B that reflects a distinguished public health service career as well experience in the management of large clinical trials for new vaccine and antiviral products. Most recently, he was Vice President, Clinical Development at Osel, Inc., a bacterial therapeutics company and prior to that, a Founding Member and President of Quattro Clinical Research, a clinical research organization providing clinical research services to biotechnology and pharmaceutical companies developing therapeutics and anti-viral products. From 2000 to 2004, Dr. Heyward was Vice President of International Clinical Research at VaxGen, Inc. where he provided oversight for two major Phase 3 clinical trials evaluating an HIV vaccine in 7500 subjects at over 60 U.S. and international sites. Over a period of 20 years, Dr. Heyward was a Commissioned Officer in the U.S. Public Health Service with the U.S. Centers for Disease Control and Prevention (CDC), where he was involved in epidemiologic and vaccine studies on a number of different infectious diseases including hepatitis B, Haemophilus influenzae type b, pneumococcal disease, botulism, and HIV/AIDS. Most notably, he led a research team in Alaska that demonstrated the role of universal immunization in the eradication of hepatitis B infection in endemic population groups. Dr. Heyward holds a M.D. from the Medical College of Georgia, a M.P.H. in Epidemiology from Johns Hopkins University School of Hygiene and Public Health, and a B.A. in Chemistry from Emory University.

Inducement Plan

To induce qualified individuals to join Dynavax, the Company's Board of Directors has adopted a 2010 Employment Inducement Award Plan (the "Inducement Plan"). This Inducement Plan provides for the issuance of up to 1,500,000 shares of Dynavax Common Stock to new employees of Dynavax. Stockholder approval of the Inducement Plan is not required under Nasdaq Marketplace Rule 5635(c)(4).

Under this Inducement Plan, nine employees, including Mr. Biehn and Dr. Heyward, were granted options to purchase a total of 648,000 shares of Dynavax Common Stock on January 11, 2010. The exercise price for the option shares granted was $1.59, which was the closing price of Dynavax Common Stock on the Nasdaq Capital Market on the date of grant.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information, visit www.dynavax.com.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies Corporation

http://www2.marketwire.com/mw/emailprcntct?id=9EF223F0779A1C…


http://investors.dynavax.com/releaseDetail.cfm?ReleaseID=436…

[Lucky72]

Wednesday January 13, 2010
Short Quote™
Enter Symbol:

Dynavax Technologies Corp.

$ 1.54
DVAX
-0.05
Short Interest (Shares Short)
510,700
Days To Cover (Short Interest Ratio)
1.8
Short Percent of Float
2.35 %
Short Interest - Prior
843,900
Short % Increase / Decrease
-0.51 %
Short Squeeze Ranking™
3

http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

Die Shorty fangen an zu covern!

Sie sind wohl auch der Meinung das es langsam teuer wird!

[Lucky72]

[Lucky72]

Mit Miniposis wird der Kurs gedrückt!

[Lucky72]

Test!

[Lucky72]

[Lucky72]

Keine News!?

[Lucky72]

Dynavax Technologies names 2 senior executives
January 15, 2010

Dynavax Technologies Corp. announced Jan. 12 the addition of two new senior executives to direct key commercial and clinical activities prior to the launch of Heplisav, an investigational adult hepatitis B vaccine.

Brant Biehn, after more than 20 years with Merck, joins as chief commercial development officer. He will be responsible for the development and execution of Dynavax's commercial strategy, including market development, sales and distribution channel partnerships.

Since 2005, Biehn was responsible for many adult vaccine products, including Merck's Hepatitis A, Hepatitis B and pneumococcal vaccines. Most recently, he served as international market lead for Zostavax, a vaccine launched in the United States in 2005 for the prevention of shingles as well as Merck's other adult vaccines.

William Heyward, M.D., an epidemiologist and specialist in the design and conduct of licensure-directed clinical trials, joins Dynavax as vice president of clinical research. He will manage the company's two registration trials for Heplisav, for which approximately 70 centers in North America and Europe will enroll 2,600 subjects.

Most recently, he was vice president of clinical development at Osel Inc., a bacterial therapeutics company and prior to that, a founding member and president of Quattro Clinical Research, a clinical research organization providing clinical research services to biotechnology and pharmaceutical companies developing therapeutics and anti-viral products.


http://vaccinenewsdaily.com/news/211649-dynavax-technologies…

[Lucky72]

Lausiges Volumen!

[Lucky72]

Nur zur Info!

http://www.mffais.com/dvax

[Lucky72]

[Lucky72]

Fette Käufe und dann wird mit "Miniposis" der Kurs gedrückt!

[Lucky72]

Guten Morgen

Ich wünsche allen einen dunkelgrünen Tag!

[Lucky72]

Hat sich Dynavax neu ausgerichtet?



http://www.dynavax.com/pipeline.html

[Lucky72]

Zum Vergleich!

[Lucky72]

Last Trade 1.46 -0.04 (-2.67%)
23,450 Volume
11:00:57 AM EST
Trade Time

[Lucky72]

Ohne News kackt sie immer weiter ab!!!

[Stefan_Borgi]

Hallo, was haltet ihr hier von ?

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=440…

gruß

[Lucky72]

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=440…

[Lucky72]

[Lucky72]

Antwort auf Beitrag Nr.: 38.813.629 von Stefan_Borgi am 26.01.10 14:42:11

Hört sich nicht schlecht an!

[Lucky72]

Droge der Hepatitis C des UPDATES 2-Dynavax ist im Versuch der Phase 1 viel versprechend
Tue 26. Januar 2010 1:36 P.M. EST

* Droge SD-101 war sichere und gezeigte Antivirenantwort

* Alle Patienten an der höchsten Dosis sahen Verkleinerung in der Virenlast

* Co sagt in den Gesprächen mit möglichen Partnern auf der Droge

* Anteile steigen soviel wie 23 pct an (addiert Firmaanmerkungen; aktualisiert auf lagerbewegung)

Durch Esha Dey

BANGALORE, 26. Januar (Reuters) - Dynavax Technologies Corp (DVAX.O) sagte, dass seine experimentelle Behandlung für chronische Infektion der Hepatitis C sichere und verursachte Antivirentätigkeit bei Patienten in einem Frühstadium Versuch war, den Anteilen der Firma soviel wie 23 Prozent oben schickend.

Der Drogeentwickler, der auf Infektionskrankheiten sich konzentriert, ist z.Z. innen frühe Gespräche mit möglichen Marketing-Partnern, die der Firma helfen können, die Droge zu entwickeln, sein leitender Geschäftsbeamter (CBO) erklärte Reuters in einem Interview.

„Dieses wird ein komplizierter, entwickelnder Bereich, der eine bedeutende Menge Weltklugheit und Kapital erfordert, das Molekül passend zu entwickeln,“ CBO Michael, den Ostrach sagte.

Die Therapie der Hepatitis C der Firma, SD-101, ist entworfen, im Verbindung mit Mundantivirals, einschließlich Standard--vonsorgfalt und auftauchende Therapien verwendet zu werden, um Reproduktion des Virus der Hepatitis C zu stoppen und eine langlebige immune Antwort zu verursachen.

Hepatitis C ist eine Infektionskrankheit, die zu zirrhose der Leber führen kann.

Jedoch sagte Ostrach die Betriebsmittel der Firma, menschlich und finanziell, werden z.Z. seinem Spätstadium Produkt, ein Impfstoff der Hepatitis B, Heplisav gewidmet.

„Beide von einer Sachkenntnis, sowie einen Hilfsmittelgesichtspunkt, die Entwicklung von Hepatitis C therapeutisch ist nicht etwas, das wir im Augenblick tun können,“ Ostrach hinzufügten.

Dynavax berichtete $46.4 über Million im Gesamtbargeld an Sept. 30, 2009.

Ostrach sagte, dass die Firma auch in den Diskussionen mit Parteien auf möglichen ex-U.S. Marketing-Teilhaberschaften für Heplisav ist.

Heplisav wurde auf einen klinischen Einfluss durch die US-Regler im März 2008 wegen der Sicherheitsinteressen gesetzt, aber der Einfluss wurde im September letztes Jahr angehoben. [Identifikation: nN09475398]

VIEL VERSPRECHENDER VERSUCH DER HEPATITIS-C

Der Frühstadium Versuch wertete vier Dosisniveaus der Droge, SD-101 aus, in 34 chronisch angesteckt, Behandlung-naive Patienten der Hepatitis C, und alle Patienten an der höchsten Dosis gezeigt erfuhr eine Verkleinerung in der Virenlast oder die Schwierigkeit der Vireninfektion. Dynavax gab auch die Resultate von einer in-vitrostudie des Mechanismus der Droge der Tätigkeit in den menschlichen Blutzellen bekannt.

Die Studie zeigte SD-101 angeregte viel höhere Niveaus von zwei bestimmten Arten Interferon oder Proteine, die durch den Körper in Erwiderung auf das Vorhandensein der Viren und des Bakteriums freigegeben werden, verglichen mit Erste-Generationsdrogen der gleichen Art.

Dynavaxs Ostrach sagte auch, dass die Firma erwartet, über Daten von einem Frühstadium Versuch seiner experimentellen Droge der Hepatitis B, DV-601, in mid-2010 zu berichten.

Es gibt keine Heilung für die Hepatitis B und der einzige Impfstoff auf dem Markt ist GlaxoSmithKline Plc (GSK.L) Engerix-B.

Anteile von Dynavax waren herauf 11 Prozent bis $1.66 im Nachmittagshandel auf Nasdaq. Sie berührten eine Höhe von $1.83 zuvor. (Bericht durch Esha Dey in Bangalore; Redigieren durch Aradhana Aravindan)

[Lucky72]

[Joe_Trader]

Antwort auf Beitrag Nr.: 38.817.213 von Lucky72 am 26.01.10 20:43:16

kennst du einen ungefähren bereich für phase 3 und FDA ??
viel glück

[Lucky72]

Antwort auf Beitrag Nr.: 38.817.977 von Joe_Trader am 26.01.10 22:10:48

phase 3 und FDA??

Was ist das? Kann man das essen?

[Lucky72]

Hier ist der Chart!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection
In vitro Study Shows SD-101 Induces Both IFN-lambda and IFN-alpha

BERKELEY, CA, Jan 26, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist (1) is well tolerated and safe and (2) induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.

Data from the Phase 1b study of SD-101 in treatment-naive, genotype 1 HCV patients show:

-- A safety and tolerability profile that compares favorably to that of
IFN-alpha, at all four doses tested;
-- A dose-dependent antiviral response, with 100% of patients at the
highest dose experiencing a greater than one (1) log reduction in viral
load; and
-- The potency of SD-101 as confirmed by biomarker analysis in patients.
The biomarker data point to substantial, dose-related increases in the
expression of key antiviral genes (MX-B and ISG-54k) and genes indicating
enhanced immunity (IP-10 and MCP-1).



The Phase 1b study evaluated four dose levels of SD-101 in 34 chronically infected, treatment-naive, genotype 1 HCV patients. SD-101 was administered as a monotherapy once weekly, for four weeks, in doses from 0.1 to 5.0 milligrams per week.

The in vitro data from a study of the drug in human blood cells demonstrate that compared to first-generation TLR9 agonists, SD-101 stimulates 20-fold higher levels of both IFN-alpha and IFN-lambda, two classes of IFNs with potent activity against HCV.

[Lucky72]

Guten Morgen


Ich wünsche uns einen grünen Tag!

[Lucky72]

Gestern war nur ein kleines Vorspiel!

Meiner Meinung nach sollte es heute richtig UUUUPPPP gehn!

[Lucky72]

Was geht den heute ab?

[Lucky72]

Gap close!!

[Lucky72]

Nanu!

[Lucky72]

Ist das wieder langweilig!

[Lucky72]

http://investors.dynavax.com/secfiling.cfm?filingID=1181431-…

[Lucky72]

Dino, wir brauchen News!

[Lucky72]

Guten Morgen

Ich denke mal heute gehts wieder UUUPPPP!

[Lucky72]

Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)

BERKELEY, CA, Feb 08, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today initiation of a large-scale Phase 3 trial designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV(TM), the Company's investigational adult hepatitis B vaccine. This study and the ongoing Phase 3 trial in chronic kidney disease patients are directed toward fulfilling licensure requirements in the U.S., Canada and Europe. HEPLISAV has been shown in two pivotal Phase 3 trials to enhance protection more rapidly and with fewer doses than a currently licensed vaccine.

The lot-to-lot consistency trial will enroll 2,000 patients in Canada and in the U.S., 1600 of whom will receive HEPLISAV. Patients randomized to the comparator arm will receive Engerix-B(R), a currently licensed hepatitis B vaccine. The primary objectives are:

-- Non-inferiority of the immune response to HEPLISAV vaccination as
measured by the seroprotection rate at 8 weeks after the last active
dose, compared to Engerix-B vaccination at 8 weeks after the last
active dose; and
-- Lot-to-lot consistency for immune response as measured by geometric
mean concentration at 4 weeks after the last active dose among 3
consecutively manufactured lots of HEPLISAV.


The secondary objectives include the safety of HEPLISAV as compared to Engerix-B.

Data from this trial is expected in the first half of 2011. The hepatitis B surface antigen in the HEPLISAV lots being evaluated was produced in Dynavax's manufacturing facility in Duesseldorf, Germany. This facility was recently upgraded and licensed in the European Union for commercial production of hepatitis B surface antigen.

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine. In a completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.

Engerix-B(R) is a trademark of GlaxoSmithKline.

About Hepatitis B Vaccines

Currently available hepatitis B vaccines require three doses over six months to achieve full immunogenicity in healthy patient populations. Because compliance with this vaccine regimen is low, new vaccines are needed to provide increased protection in a shorter timeframe. Furthermore, currently available vaccines do not fully address the needs of several patient populations, including those with chronic kidney disease, HIV or chronic liver disease. In particular, patients with comprised immune systems require both rapid and enhanced protection, either because they are less responsive to conventional vaccine regimens or because they are at high risk of infection.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward-looking Statements

This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties, including expectations of clinical trial regulatory requirements for HEPLISAV. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development or clinical trial enrollment, whether the studies can support registration for commercialization of HEPLISAV, the commercial potential for HEPLISAV and the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies


http://investors.dynavax.com/releasedetail.cfm?ReleaseID=443…

[Lucky72]

Pre-Market Charts | After Hours Charts Feb. 8, 2010 Market Close: $ 1.44

After Hours Last:1.54
After Hours High: $ 1.80
After Hours Volume: 53,103
After Hours Low: $ 1.43

[Lucky72]

Antwort auf Beitrag Nr.: 38.907.771 von Lucky72 am 09.02.10 08:58:08

Quelle http://www.nasdaq.com/aspxcontent/ExtendedTradingCharts.aspx…

[Lucky72]

Ich hoffe heute gets richtig UP!

[Lucky72]

WOW!!!

2010-02-08 2009-12-31 13F-HR Hughes Howard Medical Institute Institution 1,222,000 New Holding


2010-02-08 2009-12-31 13F-HR William Harris Investors Inc Institution 967,600 Added More

http://www.mffais.com/dvax

[Lucky72]

[Lucky72]

2010-02-09 2009-12-31 13F-HR California Public Employees Retirement System Institution 127,000 New Holding

[Lucky72]

http://investors.dynavax.com/secfiling.cfm?filingID=921895-1…

[Lucky72]

Last Trade: 1.54
Trade Time: 11:35am ET
Change: Up 0.03 (1.99%)
Prev Close: 1.51
Open: 1.54
Bid: 1.53 x 1000
Ask: 1.54 x 35500

[Lucky72]

Kein Volumen! Die Amis machen wohl Mittagsschlaf!

[Lucky72]

NEWS!!!!!

Dynavax Receives Canadian Approval to Conduct Phase 3 Trials of HEPLISAV(TM)

BERKELEY, CA, Feb 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced that Health Canada, the Canadian equivalent of the U.S. Food and Drug Administration, has approved the initiation of the Company's next Phase 3 trials in Canada. Initiation of the Canadian studies is expected to facilitate enrollment for the multi-center trials. Immunizations in the U.S. have begun, while the Canadian sites are expected to begin enrollment shortly. In Canada, the Health Products and Food Branch (HPFB) of Health Canada regulates the development of new drugs and vaccines.

One trial is designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV(TM), the Company's investigational adult hepatitis B vaccine. The second trial compares HEPLISAV to Engerix-B(R) in patients with chronic kidney disease. These studies are directed toward fulfilling licensure requirements in Canada, in addition to the U.S and Europe. HEPLISAV has been shown in two previous Phase 3 trials to enhance protection more rapidly and with fewer doses than a currently licensed vaccine.

The lot-to-lot consistency trial will enroll approximately 2,000 patients in Canada and in the U.S., 1600 of whom will receive HEPLISAV. Patients randomized to the comparator arm will receive Engerix-B, a currently licensed hepatitis B vaccine. The chronic kidney disease trial will enroll approximately 600 patients in Canada, the U.S. and Germany, 300 of whom will receive HEPLISAV. Patients randomized to the comparator arm will receive Engerix-B.

Data from these trials are expected in mid-2011. The hepatitis B surface antigen in the HEPLISAV lots being evaluated was produced in Dynavax's manufacturing facility in Duesseldorf, Germany. This facility was recently upgraded and licensed in the European Union for commercial production of hepatitis B surface antigen.

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine. In a completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.

About Hepatitis B Vaccines

Currently available hepatitis B vaccines require three doses over six months to achieve full immunogenicity in healthy patient populations. Because compliance with this vaccine regimen is low, new vaccines are needed to provide increased protection in a shorter timeframe. Furthermore, currently available vaccines do not fully address the needs of several patient populations, including those with chronic kidney disease, HIV or chronic liver disease. In particular, patients with comprised immune systems require both rapid and enhanced protection, either because they are less responsive to conventional vaccine regimens or because they are at high risk of infection.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward-looking Statements

This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties, including statements regarding the nature of planned HEPLISAV clinical trials and the timing of their initiation and completion. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development or clinical trial enrollment, whether the studies can support registration for commercialization of HEPLISAV, the commercial potential for HEPLISAV and the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Engerix-B(R) is a trademark of GlaxoSmithKline.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies


http://investors.dynavax.com/releasedetail.cfm?ReleaseID=445…

[Lucky72]

Dynavax empfängt kanadische Zustimmung, um Versuche der Phasen-3 von HEPLISAV (TM) zu leiten
Datum: 02/16/2010 @ 4:15 P.M.
Quelle: MarketWire
Vorrat: Dynavax Technologien (DVAX)
Anführungsstrich: 1.5 -0.01 (- 0.66%) @ 7:22 MORGENS


Dynavax empfängt kanadische Zustimmung, um Versuche der Phasen-3 von HEPLISAV (TM) zu leiten

BERKELEY, CA -- (Marketwire) -- 02/16/10 --

Dynavax Technologies Corporation (Nasdaq: DVAX) verkündet dieser Gesundheit Kanada, das kanadische Äquivalent der US.

Behörde zur Überwachung von Nahrungs- und Arzneimitteln, hat die Einführung die folgenden Versuche der Phase 3 der Firma in Kanada genehmigt. Einführung der kanadischen Studien wird erwartet, um Einschreibung für die Multi-centerversuche zu erleichtern.

Immunisierungen in den US haben angefangen, während die kanadischen Aufstellungsorte erwartet werden, um Einschreibung kurz anzufangen. In Kanada reguliert die Gesundheits-Produkte und die Nahrungsmittelniederlassung (HPFB) der Gesundheit Kanada die Entwicklung der neuen Drogen und der Impfstoffe.

Ein Versuch ist, um die Los-zulos Übereinstimmung des Handelsimpfstoffs zu zeigen entworfen und die Sicherheitsdatenbank für HEPLISAV ™, den erwachsenen Untersuchungsimpfstoff der Hepatitis B der Firma abzuschließen. Der zweite Versuch vergleicht HEPLISAV mit Engerix-B® bei Patienten mit chronischer Nierekrankheit.

Diese Studien werden auf befriedigende licensure Anforderungen in Kanada, zusätzlich zusätzlich den US und zum Europa gerichtet. HEPLISAV ist in zwei vorhergehenden Versuchen der Phase 3 gezeigt worden, um Schutz schnell zu erhöhen und mit wenigen Dosen als ein z.Z. genehmigter Impfstoff.

Der Los-zulos Übereinstimmungsversuch schreibt ungefähr 2.000 Patienten in Kanada und in den US, 1600 von ein, empfängt wem HEPLISAV. Die Patienten, die zum Komparatorarm randomisiert werden, empfangen Engerix-B, einen z.Z. genehmigten Impfstoff der Hepatitis B. Der chronische Nierekrankheitversuch schreibt ungefähr 600 Patienten in Kanada, in den US und in Deutschland, 300 von ein, empfängt wem HEPLISAV. Die Patienten, die zum Komparatorarm randomisiert werden, empfangen Engerix-B.

Daten von diesen Versuchen werden in mid-2011 erwartet. Das Oberflächenantigen der Hepatitis B in den HEPLISAV Losen, die ausgewertet wurden, wurde Dynavaxs in der Produktionsanlage in Düsseldorf, Deutschland produziert. Diese Anlage wurde vor kurzem in der Europäischen Gemeinschaft für wirtschaftlich lohnende Produktion des Oberflächenantigens der Hepatitis B verbessert und genehmigt.

Über HEPLISAV

HEPLISAV ist ein erwachsener Untersuchungsimpfstoff der Hepatitis B. In einem abgeschlossenen Angelversuch der phase 3 zeigte HEPLISAV erhöhten, schnellen Schutz mit wenigen Dosen als gegenwärtige genehmigte Impfstoffe. Dynavax hat weltweite Handelsrechte zu HEPLISAV und entwickelt den Impfstoff für die großen, hochwertigen Bevölkerungen, die gegenwärtigen genehmigten Impfstoffen weniger entgegenkommend sind, einschließlich Einzelpersonen mit chronischer Nierekrankheit. HEPLISAV kombiniert Oberflächenantigen der Hepatitis B mit einem Eigentümer Abgabe-wie dem Agonisten des Empfängers 9, der als ISS bekannt ist, um die immune Antwort zu erhöhen.

Über Impfstoffe der Hepatitis-B

Zurzeit verfügbare Impfstoffe der Hepatitis B erfordern drei Dosen in sechs Monaten, volle Immunisierungsfähigkeit in den gesunden geduldigen Bevölkerungen zu erzielen.

Weil Befolgung dieser vaccine Regierung niedrig ist, sind neue Impfstoffe erforderlich, erhöhten Schutz in einem kürzeren Zeitrahmen zu bieten. Außerdem sprechen zurzeit verfügbare Impfstoffe nicht völlig die Notwendigkeiten einiger geduldiger Bevölkerungen, einschließlich die mit chronischer Nierekrankheit, HIV oder chronischer Leberkrankheit an. Insbesondere fordern Patienten mit enthaltenen Immunsystemen schnellen und erhöhten Schutz, irgendeinen, weil sie herkömmlichen vaccine Regierungen weniger entgegenkommend sind, oder weil sie am hohen Risiko der Infektion sind.

Über Dynavax

Dynavax Technologies Corporation, eine Klinischstadium biopharmaceutical Firma, entdeckt und entwickelt neue Produkte, um Infektionskrankheiten zu verhindern und zu behandeln. Der Blei-Produktanwärter der Firma ist HEPLISAV, ein erwachsener Untersuchungsimpfstoff der Hepatitis B, der entworfen ist, um Schutz wenigen Dosen als gegenwärtige genehmigte Impfstoffe schnell und mit zu erhöhen. Für mehr Informationsbesuch www.dynavax.com.

Vorausschauende Aussagen

Dieses Pressekommuniqué enthält „vorausschauende Aussagen“, dass abhängig von einigen Risiken und Ungewissheiten, einschließlich Aussagen betreffend die Art der geplanten HEPLISAV klinischer Studien und das TIMING ihrer Einführung und Beendigung seien Sie. Tatsächliche Resultate können von denen materiell sich unterscheiden, die in diesem Pressekommuniqué wegen der Risiken und die Ungewissheiten zugehörig sind in unserem Geschäft festgelegt werden und umfassen, ob erfolgreiche klinische und regelnde Entwicklung und Zustimmung von HEPLISAV in einer fristgerechten Weise oder ohne bedeutende zusätzliche Studien oder Schwierigkeiten oder Verzögerungen in der Entwicklung oder in der Studieeneinschreibung auftreten können, ob die Studien Ausrichtung für Kommerzialisierung von HEPLISAV, das Handelspotential für HEPLISAV und die Fähigkeit der Firma stützen können, zusätzliche Finanzierung zu erhalten, um die Entwicklung und die Kommerzialisierung von HEPLISAV und von seinen anderen Betrieben zu stützen, mögliche Ansprüche gegen die Firma, die auf den Patentrechten von anderen basiert; und anderes riskiert ausführliches im „Risiko-Faktor“ Abschnitt unserer gegenwärtigen periodischen Reports mit der sek. Wir nehmen uns keine Verpflichtung, hierin zu verbessern oder die Updateinformationen, zum von Ereignissen oder von Umständen zukünftig zu reflektieren auf, selbst wenn neue Informationen vorhanden werden.

Engerix-B® ist ein eingetragenes Warenzeichen von GlaxoSmithKline.

Kontakt: Des Michael-Ostrach eMail-Kontakt Vizepräsidenten-und Leiter-Geschäfts-Offizier-510-665-7257

[Lucky72]

Guten Morgen

Ich wünsche uns einen dunkelgrünen Tag!

[Lucky72]

Die Jungs die gestern zu 1,49$ geschmissen haben, sind bestimmt angepi....!

[Lucky72]

Nur zur Info!

http://www.nasdaq.com/aspxcontent/ExtendedTradingCharts.aspx…

[Lucky72]

Pre-market: 1.60 +0.10 (6.67%)
Feb 17, 8:47AM EST

Das ist aber lasch!!

[Lucky72]

[Lucky72]

[Lucky72]

Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program
IND-Enabling Studies Underway

BERKELEY, CA, Feb 18, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the selection of a candidate for clinical development in its endosomal Toll-like Receptor (TLR) inhibitor collaboration with GlaxoSmithKline. The selected molecule DV1179, a bifunctional TLR inhibitor, has moved into advanced preclinical IND-enabling studies that could allow clinical development to begin as early as this year. Dynavax and GlaxoSmithKline are collaborating to develop novel inhibitors of endosomal TLRs for the treatment of multiple autoimmune and inflammatory diseases. TLRs are key receptors of the innate immune system.

Under the collaboration, Dynavax has been conducting research primarily in the area of autoimmune and sterile inflammatory diseases. GSK has a right to exercise its exclusive option to license each program upon achievement of proof-of-concept or earlier upon certain circumstances. After exercising its option, GSK will carry out further development and commercialization of these products. Dynavax will receive tiered royalties, up to double-digits, on sales and has retained an option to co-develop and co-promote one specified product. Dynavax received an initial payment of $10 million when the collaboration was announced in December 2008 in exchange for which GSK received an exclusive option over four programs targeting autoimmune and inflammatory diseases such as lupus, psoriasis, and rheumatoid arthritis.

About TLR Inhibitors

Dynavax's endosomal TLR inhibitors are a novel class of oligonucleotides, called immunoregulatory sequences (IRS), that specifically inhibit the TLR-induced inflammatory response associated with autoimmune and inflammatory diseases. Preclinical data from animal model studies show Dynavax's TLR inhibitors block induction of IFN-alpha and also reduce symptoms in multiple autoimmune diseases animal models, such as lupus, inflammatory skin disorders, and rheumatoid arthritis.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward-looking Statements

This press release contains "forward-looking statements," including statements related to the anticipated development of our inhibitors of endosomal TLRs, including initiation of clinical trials, the responsibilities of the parties under our collaboration agreement with GSK and the potential value of payments that may be received under our collaboration. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including difficulties or delays in discovery or development, initiation and completion of preclinical or clinical studies, the results of those studies and the impact of those results on the initiation and completion of subsequent studies and issues arising in the regulatory process; achieving our GSK collaborative agreement objectives; our ability to obtain additional financing to support our operations; and other risks detailed in the "Risk Factors" section of our current periodic reports filed with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies

http://investors.dynavax.com/releaseDetail.cfm?ReleaseID=445…

[Lucky72]

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Das wird heute nix mehr!

[Lucky72]

Es sollten eigentlich bald Q-Zahlen kommen!

[Lucky72]

Dino, wir brauchen Newwwws!!!

[Lucky72]

http://investors.dynavax.com/sec.cfm

[Lucky72]

NEEEWWWWS!!!!!

Dynavax Selects Clinical Candidate in Universal Flu Vaccine Program

BERKELEY, CA, Feb 25, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has selected a clinical vaccine candidate for its novel Universal Flu program, completed key preclinical studies, and is reviewing clinical plans with the FDA in anticipation of initiating a Phase I study by mid-year. Dynavax also said that the trial will be conducted at centers that are members of the Vaccine Testing and Evaluation Units (VTEUs) of the National Institute for Allergy and Infectious Disease (NIAID/NIH). Specifically, Dynavax will collaborate with Dr. Robert B. Belshe, Principal Investigator of the VTEU at St. Louis University in St. Louis, MO and with Dr. Wendy A. Keitel, Principal Investigator, of the VTEU at Baylor University in Houston, TX. Dynavax made its comments today in connection with a Workshop on Influenza Vaccinology sponsored by the President's Council of Advisors on Science and Technology in Washington, D.C.

According to Dino Dina, M.D., President and CEO, "As new pandemic threats such as the H1N1 epidemic of the 2009 flu season emerge, it is becoming increasingly clear that our Universal Flu approach represents an important intervention with the potential to provide broad protection against new strains of the influenza virus. We expect the initial data, including evidence of the biological activity of the vaccine's proprietary components, to be available this year."

Dynavax indicated that a GLP toxicity study demonstrated that its Universal Flu vaccine candidate is well-tolerated, and clinical material for the upcoming trial has been manufactured. Through the addition of two highly conserved antigens, known as NP and M2e, linked to a proprietary TLR9 agonist, Dynavax's Universal Flu vaccine is designed to offer protection against divergent influenza strains, increase the efficacy of standard vaccines, and potentially reduce the dose of vaccine to extend the quantity available during a pandemic.

Dynavax presented data on its Universal Flu vaccine at two medical conferences in 2009: Third International Conference on Influenza Vaccines for the World in Cannes, France April 27 - 30, 2009 and the Twelfth Annual Conference on Vaccine Research in Baltimore, Maryland April 27 - 29, 2009. The presentations titled "A Universal Influenza Vaccine: Generating Broad Immunity Using an M2e/NP Fusion Protein" are posted on Dynavax's website at http://investors.dynavax.com/events.cfm.

Dynavax's research and development program has been partially funded by grants from the National Institutes of Health (NIH). Dynavax has a worldwide supply and option agreement with Novartis Vaccines and Diagnostics, Inc. for the Universal Flu vaccine program and is exploring grants and other sources of funding for the Phase 1 clinical trial program.

About Dynavax's Universal Flu Vaccine

Standard annual flu vaccines are designed to provide protection against the three strains of the influenza virus that are predicted to be most prevalent in an upcoming flu season. As such, these vaccines do not provide protection against divergent strains that emerge unexpectedly.

Dynavax's novel Universal Flu vaccine is designed to offer protection against divergent strains as well as increase the efficacy and potentially reduce the dose of standard flu vaccine. This unique approach is based on combining two highly conserved antigens and Dynavax's proprietary second-generation TLR9 agonist with standard flu vaccines:

-- Two highly conserved antigens NP and M2e offer protection against
divergent strains


Dynavax's Universal Flu vaccine includes two conserved antigens, NP and M2e, which are present in all flu strains. NP, or nucleoprotein, is highly conserved across human and animal strains, while M2e, the extracellular domain of the matrix 2 protein, is conserved but with some variations among species. NP provides cytotoxic T-cell protection and M2e offers protective antibodies for protection against divergent strains.

-- Dynavax's proprietary second-generation TLR9 agonist to enhance efficacy
and enable dose-sparing


The conserved antigens NP and M2e are linked to Dynavax's proprietary second-generation TLR9 agonist. This approach has demonstrated the potential to boost the immune response and enable dose sparing, which could extend the quantity of standard flu vaccine available during a pandemic.

-- Standard flu vaccine


Dynavax's Universal Flu vaccine combines the conserved antigens NP and M2e with the Company's proprietary TLR9 agonist and the standard vaccine, which provides neutralizing antibodies. The Company's proprietary component (NP/M2e-ISS) could be combined with any standard flu vaccine, including standard trivalent influenza vaccine (TIV), and emerging strains such as H5N1 or H1N1.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV(TM), an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information, visit www.dynavax.com.

Forward-looking Statements

This press release contains "forward-looking statements," including statements related to our Universal Flu vaccine, including the anticipated timing and investigators for the initial clinical trial, the availability of resulting data and the potential of the vaccine. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including difficulties or delays in discovery or development, initiation and completion of preclinical or clinical studies, the results of those studies and the impact of those results on the initiation and completion of subsequent studies and issues arising in the regulatory process; achieving our Novartis agreement objectives; our ability to obtain additional financing to support our operations; and other risks detailed in the "Risk Factors" section of our current periodic reports filed with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies


http://investors.dynavax.com/releasedetail.cfm?ReleaseID=447…

[Lucky72]

Time & Sales
Price Size Exch Time
1.48 254 NGS 16:00:01
1.52 100 NDD 15:59:57
1.52 100 NDD 15:59:50
1.52 100 NDD 15:59:31
1.51 127 BATS 15:59:22
1.51 100 NDD 15:59:20
1.51 100 NDD 15:59:20
1.51 100 NDD 15:59:20
1.52 200 NDD 15:58:38
1.52 100 ISE 15:58:05
1.52 100 NDD 15:56:42
1.52 200 NDD 15:56:42

[Lucky72]

Dynavax Technologies Corp.

$ 1.46
DVAX
-0.02
Short Interest (Shares Short)
346,100
Days To Cover (Short Interest Ratio)
1.5
Short Percent of Float
0.97 %
Short Interest - Prior
374,200
Short % Increase / Decrease
-7.51 %
Short Squeeze Ranking™
2
% From 52-Wk High ($ 3.35 )
-129.45 %
% From 52-Wk Low ($ 0.50 )
65.75 %
% From 200-Day MA ($ 1.56 )
-6.85 %
% From 50-Day MA ($ 1.52 )
-4.11 %
Price % Change (52-Week)
155.20 %
Shares Float
35,632,044
Total Shares Outstanding
54,279,270
% Owned by Insiders
10.20 %
% Owned by Institutions
27.10 %
Market Cap.

$ 79,247,734
Trading Volume - Today
81,526
Trading Volume - Average
234,500
Trading Volume - Today vs. Average
34.77 %
Earnings Per Share
0.07
PE Ratio
20.90
Record Date
2010-FebB

http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

Heute sollten die Zahlen für 2009 kommen!

[Lucky72]

[Lucky72]

Das wird heut wohl wieder nix!

[Lucky72]

Dann laß ich mal den Affen raus!

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.036.531 von Lucky72 am 01.03.10 21:22:50

Wegen 4cent ?? Der Affe sieht so aus als würde er am liebsten dir das Plakat um die Ohren hauen

[Lucky72]

Antwort auf Beitrag Nr.: 39.036.554 von BrauchGeld am 01.03.10 21:26:34

Wegen 4cent ??

Das kommt noch!

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.036.671 von Lucky72 am 01.03.10 21:43:47

Weißt du überhaupt in was du da dein geld gesteckt hast ???

Heplisav muss durch eine neue PIII-Studie um eine Chance auf die Zulassung zu haben und das wird viel geld verschlingen .



Pipeline ist ziemlich Schwach ..

[Lucky72]

Antwort auf Beitrag Nr.: 39.036.725 von BrauchGeld am 01.03.10 21:50:46

Ich denke schon und hoffe das die "Jungs" das auch wissen!

http://data.cnbc.com/quotes/DVAX/tab/8

[Lucky72]

Wo bleiben die Zahlen????

[Lucky72]

[Lucky72]

Ist das die Ruhe vor dem Sturm?

[Lucky72]

Last Trade: 1.49
Trade Time: 2:26pm ET
Change: Down 0.02 (1.32%)
Prev Close: 1.51
Open: 1.50
Bid: 1.48 x 37900
Ask: 1.49 x 1700

[Lucky72]

Seit zwei Wochen keine News!!

Die Zahlen sind auch überfällig!

[Lucky72]

Jetzt aber raus mit der News!

[Lucky72]

Guten Morgen

Ich wünsche allen einen dunkelgrünen Tag!

[Lucky72]

Die Shorty gehn wohl auch von steigenden Kursen aus!



Dynavax Technologies Corp.

$ 1.54
DVAX
0.05
Short Interest (Shares Short)
236,700
Days To Cover (Short Interest Ratio)
1.1
Short Percent of Float
0.66 %
Short Interest - Prior
346,100
Short % Increase / Decrease
-31.61 %
Short Squeeze Ranking™
1
% From 52-Wk High ($ 3.35 )
-117.53 %
% From 52-Wk Low ($ 0.51 )
66.88 %
% From 200-Day MA ($ 1.55 )
-0.65 %
% From 50-Day MA ($ 1.50 )
2.60 %
Price % Change (52-Week)
192.20 %
Shares Float
35,632,044
Total Shares Outstanding
54,279,270
% Owned by Insiders
10.20 %
% Owned by Institutions
27.10 %
Market Cap.

$ 83,590,076
Trading Volume - Today
235,081
Trading Volume - Average
209,500
Trading Volume - Today vs. Average
112.21 %
Earnings Per Share
0.07
PE Ratio
21.30
Record Date
2010-MarA
Sector
Healthcare
Industry
Drug Manufacturers - Other
Exchange
NAS


http://www.shortsqueeze.com/?symbol=DVAX&submit=Short+Quote%…

[Lucky72]

[Lucky72]

Hier mal der Chart!

http://stockcharts.com/h-sc/ui?s=DVAX&p=D&yr=0&mn=3&dy=0&id=…

[Lucky72]

Dino könnte langsam mal die Katze aus dem Sack lassen!

[Lucky72]

Ob wir heute noch die 1,80$ sehn!?

[Lucky72]

Naja fast!

[Lucky72]

Guten Morgen

[Lucky72]

Das war ja gestern ein geiler Anstieg!

Und alles ohne News!

[Lucky72]

Dynavax and Merck Agree on Final Reimbursements
Merck to Make $4 Million Payment to Dynavax

BERKELEY, CA, Mar 15, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the successful completion of negotiations relating to Merck's reimbursement obligations under the former partnership agreements covering the clinical development and commercialization of HEPLISAV(TM), Dynavax's enhanced hepatitis B vaccine. Merck has agreed to make a $4.0 million payment to Dynavax covering expenses for the wind down period that followed its December 2008 written notification of the collaboration's conclusion.

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine. The vaccine candidate is being evaluated in two Phase 3 studies that are directed toward fulfilling licensure requirements in U.S., Canada and Europe. In a completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.

About Hepatitis B Vaccines

Currently available hepatitis B vaccines require three doses over six months to achieve full immunogenicity in healthy patient populations. Because compliance with this vaccine regimen is low, new vaccines are needed to provide increased protection in a shorter timeframe. Furthermore, currently available vaccines do not fully address the needs of several patient populations, including those with chronic kidney disease, HIV or chronic liver disease. In particular, patients with comprised immune systems require both rapid and enhanced protection, either because they are less responsive to conventional vaccine regimens or because they are at high risk of infection.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward-looking Statements

This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties, including statements regarding the nature of HEPLISAV clinical trials required for BLA submission. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development or clinical trial enrollment, whether the studies can support registration for commercialization of HEPLISAV, the commercial potential for HEPLISAV and the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



SOURCE: Dynavax Technologies

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=451…

[Lucky72]

Dynavax To Receive $4 Mln As Final Reimbursement From Merck Under Terminated Agreement For Heplisav - Update


(RTTNews) - Monday, Dynavax Technologies Corp. (DVAX) announced that it will receive $4 million from Merck & Co. Inc. (MRK) as final reimbursement under a former partnership agreement for clinical development and commercialization of investigational hepatitis B vaccine Heplisav.

The amount will cover Dynavax' expenses for the wind down period that followed the collaboration's conclusion in December 2008.

Heplisav was put on clinical hold in March 2008 after a single case of Wegener's granulomatosis was reported in a phase III healthy adult study conducted outside the U.S. Wegener's granulomatosis is an uncommon disease in which the blood vessels are inflamed.

In October 2008, the regulatory agency requested additional information prior to considering further development of Heplisav in end-stage renal disease patients but advised that the balance of risk versus potential benefit no longer favors continued clinical evaluation of Heplisav in healthy adults and children.

In the wake of regulatory issues, Merck, which had licensed exclusive worldwide rights to Heplisav from Dynavax, terminated its partnership on December 19, 2008 and handed over all the rights back to Dynavax. The licensing deal was worth $31.5 million up front and up to $105 million in milestone payments.

Dynavax commenced a late-stage registration trial for Heplisav in individuals with chronic kidney disease in September 2009 after an 18-month hold. The vaccine is studied for both healthy adults and patients with end-stage renal disease.

DVAX closed Friday's trading at $1.57, down 4.27% on a volume of 208 thousand shares.

For comments and feedback: contact [e-mail]


http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[Lucky72]

Dynavax Anticipates Earlier BLA Submission for HEPLISAV(TM)
2009 Financial Results Reviewed

BERKELEY, CA, Mar 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today said that its large-scale Phase 3 study of HEPLISAV(TM) is fully enrolled, with immunization of subjects proceeding in accordance with the pre-specified safety monitoring plan. Dynavax indicated that it expects immunization of all 2,000 subjects with HEPLISAV in the lot-to-lot consistency study will be completed in the near future, an achievement that creates the opportunity to submit a BLA in the third quarter of 2011, approximately six months earlier than previously projected.

According to Dino Dina, M.D., President and CEO, "The accelerated enrollment and immunization of subjects for the safety and consistency study of HEPLISAV is an important accomplishment that we expect will facilitate the successful conclusion of several ongoing financing discussions. Clearly, this is our highest priority to ensure the success of the program."

Dynavax separately reported $36.7 million in unrestricted cash and cash equivalents at December 31, 2009. This compares to $46.4 million at September 30, 2009, of which $21.7 million were investments held by Symphony Dynamo, Inc. (SDI). The $9.7 million burn for the fourth quarter primarily reflected intensified activities relating to the initiation of the two Phase 3 multi-center trials for HEPLISAV in the U.S., Canada and Germany. The year-end 2009 results do not include a $4.0 million payment due from Merck as announced this week. The results do not reflect a separate $1.8 million payment from AstraZeneca representing a reimbursement adjustment for 2009 and prior periods.

Today Dynavax filed its annual report on Form 10-K for the fiscal year ended December 31, 2009 with the Securities and Exchange Commission (SEC). As a result of the Company's current financial position, Dynavax's independent registered public accounting firm has included a statement regarding the Company's ability to continue as a going concern in its unqualified opinion contained in the Form 10-K. This announcement is being made in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of a recent audit opinion that contains "going concern" explanatory language. Management's plan to address the Company's liquidity requirements and a more detailed discussion of the financial results is provided in the Form 10-K.

The tables included as part of this press release provide a reconciliation of GAAP revenues and operating expenses to pro forma revenues and operating expenses.

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine. The vaccine candidate is being evaluated in two Phase 3 studies that are directed toward fulfilling licensure requirements in U.S., Canada and Europe. In a completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.

About Hepatitis B Vaccines

Currently available hepatitis B vaccines require three doses over six months to achieve full immunogenicity in healthy patient populations. Because compliance with this vaccine regimen is low, new vaccines are needed to provide increased protection in a shorter timeframe. Furthermore, currently available vaccines do not fully address the needs of several patient populations, including those with chronic kidney disease, HIV or chronic liver disease. In particular, patients with comprised immune systems require both rapid and enhanced protection, either because they are less responsive to conventional vaccine regimens or because they are at high risk of infection.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward Looking Statements

This press release contains "forward-looking statements," that are subject to a number of risks and uncertainties, including statements relating to clinical trial status, BLA submission and financing. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development or clinical trial enrollment, whether the studies can support registration for commercialization of HEPLISAV; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process; the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in the Company's current periodic reports with the SEC.

- tables to follow -

http://investors.dynavax.com/releasedetail.cfm?ReleaseID=452…

[Lucky72]

March 16, 2010, 8:03 a.m.
Dynavax Anticipates Earlier BLA Submission for HEPLISAV(TM)
2009 Financial Results Reviewed

BERKELEY, CA, Mar 16, 2010 (MARKETWIRE via COMTEX) -- Dynavax Technologies Corporation /quotes/comstock/15*!dvax/quotes/nls/dvax (DVAX 1.53, -0.06, -3.77%) today said that its large-scale Phase 3 study of HEPLISAV(TM) is fully enrolled, with immunization of subjects proceeding in accordance with the pre-specified safety monitoring plan. Dynavax indicated that it expects immunization of all 2,000 subjects with HEPLISAV in the lot-to-lot consistency study will be completed in the near future, an achievement that creates the opportunity to submit a BLA in the third quarter of 2011, approximately six months earlier than previously projected.

According to Dino Dina, M.D., President and CEO, "The accelerated enrollment and immunization of subjects for the safety and consistency study of HEPLISAV is an important accomplishment that we expect will facilitate the successful conclusion of several ongoing financing discussions. Clearly, this is our highest priority to ensure the success of the program."

Dynavax separately reported $36.7 million in unrestricted cash and cash equivalents at December 31, 2009. This compares to $46.4 million at September 30, 2009, of which $21.7 million were investments held by Symphony Dynamo, Inc. (SDI). The $9.7 million burn for the fourth quarter primarily reflected intensified activities relating to the initiation of the two Phase 3 multi-center trials for HEPLISAV in the U.S., Canada and Germany. The year-end 2009 results do not include a $4.0 million payment due from Merck as announced this week. The results do not reflect a separate $1.8 million payment from AstraZeneca representing a reimbursement adjustment for 2009 and prior periods.

Today Dynavax filed its annual report on Form 10-K for the fiscal year ended December 31, 2009 with the Securities and Exchange Commission (SEC). As a result of the Company's current financial position, Dynavax's independent registered public accounting firm has included a statement regarding the Company's ability to continue as a going concern in its unqualified opinion contained in the Form 10-K. This announcement is being made in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of a recent audit opinion that contains "going concern" explanatory language. Management's plan to address the Company's liquidity requirements and a more detailed discussion of the financial results is provided in the Form 10-K.

The tables included as part of this press release provide a reconciliation of GAAP revenues and operating expenses to pro forma revenues and operating expenses.


http://www.marketwatch.com/story/dynavax-anticipates-earlier…

[Lucky72]

[Lucky72]

Form 10-K
Annual Report
Filed Mar 16, 2010

http://investors.dynavax.com/secfiling.cfm?filingID=1193125-…

[Lucky72]

Hab heute mal nachgelegt!

[Lucky72]

Warum kackt sie heute so ab???

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.180.175 von Lucky72 am 19.03.10 18:28:29

Vielleicht weil du nachgelegt hast

[Lucky72]

Antwort auf Beitrag Nr.: 39.180.335 von BrauchGeld am 19.03.10 18:52:56

Dann leg ich eben nochmal nach!

[Lucky72]

Wer verkauft bei diesem Preis??

Hier sind wohl Shorty am Werk!!

[Lucky72]

Warum verkaufen die "BIG Boys" ihre Aktien nicht?!

http://data.cnbc.com/quotes/DVAX/tab/8

Die wissen wohl mehr!

[KillingJoke]

Antwort auf Beitrag Nr.: 39.194.675 von Lucky72 am 23.03.10 08:41:22

Heute interessante News:

Dynavax Reports Positive Findings From Detailed Safety Analysis of HEPLISAV(TM)
Comparable Safety Profile to Approved Commercial Vaccine; No Evidence for Increased Risk of Autoimmunity

BERKELEY, CA--(Marketwire - 03/23/10) - Dynavax Technologies Corporation (NASDAQ: DVAX - News) will present for the first time a detailed analysis of safety data for HEPLISAV™, an investigational adult hepatitis B vaccine, including two major findings:
•The safety profile of HEPLISAV was comparable to that of Engerix-B®, one of two currently licensed vaccines for the prevention of hepatitis B infection, and
•There is no difference in autoimmune adverse events or laboratory markers of autoimmunity between subjects vaccinated with HEPLISAV and Engerix-B.

Normalerweise interessieren ja mehr die Effizienzdanten. Die Verträgslichkeitsdaten sind allerdings bei der Vorgeschichte sehr wichtig. HEPLISAV war zwischen Mai 2008 und September 2009 mit einem "clinical hold" bei chronischer Nierenerkrankung (CKD) belegt.


BERKELEY, Calif.--(BUSINESS WIRE)--Sep 10, 2009 - Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.
(...) “The success of our scientific approach to resolving the clinical hold on HEPLISAV allows us to resume development of our enhanced hepatitis B vaccine,” commented Dino Dina, M.D., President and Chief Executive Officer of Dynavax. “After achieving strong efficacy data in our prior Phase 3 pivotal trial, we are fully prepared to initiate the final registration trials for HEPLISAV.”

Nach dem Absturz der letzten Tage unter 1.40 USD (gestern 1,27 USD) könnte es heute nach oben zucken.

[Lucky72]

Das sind ja geile News!

Jetzt geht den Shorty der Arsch!

[Lucky72]

[Lucky72]

Dynavax Reports Positive Findings From Detailed Safety Analysis of HEPLISAV(TM)
Comparable Safety Profile to Approved Commercial Vaccine; No Evidence for Increased Risk of Autoimmunity

BERKELEY, CA, Mar 23, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) will present for the first time a detailed analysis of safety data for HEPLISAV(TM), an investigational adult hepatitis B vaccine, including two major findings:

-- The safety profile of HEPLISAV was comparable to that of
Engerix-B(R), one of two currently licensed vaccines for the
prevention of hepatitis B infection, and
-- There is no difference in autoimmune adverse events or laboratory
markers of autoimmunity between subjects vaccinated with HEPLISAV and
Engerix-B.


The results of nine completed clinical studies comparing HEPLISAV to Engerix-B and an analysis of approximately 9,300 blood samples from subjects vaccinated with HEPLISAV or Engerix-B will be presented at the Drug Information Association's (DIA) Third Oligonucleotides-based Therapeutics Conference in Bethesda, MD on March 24, 2010. The safety data was originally prepared for submission to the FDA as part of extensive documentation that formed the basis upon which HEPLISAV's clinical development was allowed to resume in late 2009.

These data show that there was no difference between the HEPLISAV and Engerix-B groups in the occurrence of autoimmune adverse events (AEs), with 7 autoimmune AEs in 2,500 subjects immunized with HEPLISAV, a rate of 0.28%, versus 4 autoimmune AEs in 930 subjects immunized with Engerix-B, a rate of 0.43%. In addition, all other analyses presented, including AEs potentially associated with autoimmunity, anti-double stranded DNA antibodies, and ANCA antibodies, were indistinguishable between the two groups.

"Our retrospective analysis of clinical and laboratory safety from 2,500 HEPLISAV-vaccinated subjects in nine clinical trials provided no evidence of an increased risk of autoimmune disease. This thorough analysis has been discussed with the FDA and demonstrates that the safety profile of HEPLISAV is no different from that of Engerix-B, one of the safest vaccines on the market today," indicated Dr. Tyler Martin, Chief Medical Officer.

Engerix-B(R) is a trademark of GlaxoSmithKline.

Review of Previously Reported Phase 3 HEPLISAV Data

Dr. Martin also reviewed several earlier clinical studies that compared HEPLISAV to Engerix-B, and provided evidence of HEPLISAV's enhanced performance:

-- The 2004 Phase 3 study of 412 subjects age 40-70 years old found:
-- 99% seroprotection for HEPLISAV vs. 25% for Engerix-B after the
second dose;
-- Durable antibody levels that remained one year after the first
dose; and
-- Greater protection in the oldest subjects studied, specifically
between 56-70 years of age.


-- The 2008 Phase 3 "PHAST" study of more than 2,400 subjects at 21 sites
in Canada and Germany showed:
-- 98% of subjects who received two doses of HEPLISAV (n=1,819)
developed protective antibodies to hepatitis B, vs. 81% of
subjects who received three doses of Engerix-B (n=608);
-- The non-inferiority of HEPLISAV as compared to Engerix-B; and
-- A significant difference in terms of efficacy (97% vs. 75% in less
responsive populations, namely in the subject group age 40-55
years old).


-- The 2007 Phase 1 study in 75 Chronic Kidney Disease patients showed:
-- Rapid, increased protection against hepatitis B viral infection
with fewer doses (96% of patients receiving 3 doses of HEPLISAV
achieved seroprotection at month 7, compared to 88% of patients
receiving 8 doses of Engerix-B);
-- A rapid response of 83% vs. 44% seroprotection two months after
the second dose;
-- High and durable antibody levels and seroprotection; and
-- Improved seroprotection in an immunocompromised population.


About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine. The vaccine candidate is being evaluated in two Phase 3 studies that are directed toward fulfilling licensure requirements in the U.S., Canada and Europe. In a completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.

About Hepatitis B Vaccines

Currently available hepatitis B vaccines require three doses over six months to achieve full immunogenicity in healthy patient populations. Because compliance with this vaccine regimen is low, new vaccines are needed to provide increased protection in a shorter timeframe. Furthermore, currently available vaccines do not fully address the needs of several patient populations, including those with chronic kidney disease, HIV or chronic liver disease. In particular, patients with comprised immune systems require both rapid and enhanced protection, either because they are less responsive to conventional vaccine regimens or because they are at high risk of infection.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Forward-Looking Statements

This press release contains "forward-looking statements," that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether the comparability data presented in the retrospective analyses will be replicated in other clinical studies, successful clinical and regulatory development and approval of HEPLISAV can occur in a timely manner or without significant additional studies or difficulties or delays in development or clinical trial enrollment, whether the studies can support registration for commercialization of HEPLISAV; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process; the Company's ability to obtain additional financing to support the development and commercialization of HEPLISAV and its other operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in the Company's current periodic reports with the SEC.

Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact


http://investors.dynavax.com/releasedetail.cfm?ReleaseID=453…

[Lucky72]